Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID-19: Daily Top 10 Papers

  Nuclear Medicine

  Free Subscription

Articles published in J Nucl Med

Retrieve available abstracts of 467 articles:
HTML format

Single Articles

    November 2021
  1. COSTA GCA, Spencer BA, Omidvari N, Foster C, et al
    Radioembolization Dosimetry with Total-Body (90)Y PET.
    J Nucl Med. 2021 Nov 18. pii: jnumed.121.263145. doi: 10.2967/jnumed.121.263145.
    PubMed     Abstract available

  2. WANG G, Nardo L, Parikh M, Abdelhafez YG, et al
    Total-Body PET Multiparametric Imaging of Cancer Using a Voxel-wise Strategy of Compartmental Modeling.
    J Nucl Med. 2021 Nov 18. pii: jnumed.121.262668. doi: 10.2967/jnumed.121.262668.
    PubMed     Abstract available

  3. MALPETTI M, Kaalund SS, Tsvetanov KA, Rittman T, et al
    In vivo (18)F-flortaucipir PET does not accurately support the staging of progressive supranuclear palsy.
    J Nucl Med. 2021 Nov 18. pii: jnumed.121.262985. doi: 10.2967/jnumed.121.262985.
    PubMed     Abstract available

  4. THEISEN AL, Lassmann M, Tran-Gia J
    Towards a patient-specific traceable quantification of SPECT/CT-based radiopharmaceutical distributions.
    J Nucl Med. 2021 Nov 18. pii: jnumed.121.262925. doi: 10.2967/jnumed.121.262925.
    PubMed     Abstract available

  5. REDDY RP, Schmidtlein CR, Giancipoli RG, Mauguen A, et al
    The quest for an accurate functional tumor volume with (68)Ga-DOTATATE PET/CT.
    J Nucl Med. 2021 Nov 12. pii: jnumed.121.262782. doi: 10.2967/jnumed.121.262782.
    PubMed     Abstract available

  6. STELLA M, van Rooij R, Lam M, de Jong H, et al
    Lung dose measured on post-radioembolization (90)Y-PET/CT and incidence of radiation pneumonitis.
    J Nucl Med. 2021 Nov 12. pii: jnumed.121.263143. doi: 10.2967/jnumed.121.263143.
    PubMed     Abstract available

  7. SHAGERA QA, Artigas C, Karfis I, Critchi G, et al
    (68)Ga-PSMA PET/CT for response assessment and outcome prediction in metastatic prostate cancer patients treated with taxane-based chemotherapy.
    J Nucl Med. 2021 Nov 12. pii: jnumed.121.263006. doi: 10.2967/jnumed.121.263006.
    PubMed     Abstract available

  8. MONA CE, Benz MR, Hikmat F, Grogan TR, et al
    Correlation of (68)Ga-FAPi-46 PET biodistribution with FAP expression by immunohistochemistry in patients with solid cancers: a prospective translational exploratory study.
    J Nucl Med. 2021 Nov 5. pii: jnumed.121.262426. doi: 10.2967/jnumed.121.262426.
    PubMed     Abstract available

  9. BRADSHAW TJ, Boellaard R, Dutta J, Jha AK, et al
    Nuclear Medicine and Artificial Intelligence: Best Practices for Algorithm Development.
    J Nucl Med. 2021 Nov 5. pii: jnumed.121.262567. doi: 10.2967/jnumed.121.262567.
    PubMed     Abstract available

  10. YOUNIS MH, Lan X, Cai W
    PET with a (68)Ga-labeled FAPI dimer: moving towards theranostics.
    J Nucl Med. 2021 Nov 5. pii: jnumed.121.263292. doi: 10.2967/jnumed.121.263292.

  11. THUILLIER P, Liberini V, Grimaldi S, Rampado O, et al
    Prognostic value of whole-body PET volumetric parameters extracted from (68)Ga-DOTATOC-PET/CT in well-differentiated neuroendocrine tumors.
    J Nucl Med. 2021 Nov 5. pii: jnumed.121.262652. doi: 10.2967/jnumed.121.262652.
    PubMed     Abstract available

    Commercially competitive vendor-agnostic image reconstruction could be a leap forward for PET harmonization.
    J Nucl Med. 2021 Nov 5. pii: jnumed.121.263421. doi: 10.2967/jnumed.121.263421.

  13. SCOTT AM, Czernin J
    Perspectives on Theranostics and Nuclear Medicine: A Conversation Between Andrew Scott and Johannes Czernin.
    J Nucl Med. 2021;62:1492-1494.

  14. CALAIS J, Czernin J
    PSMA Expression Assessed by PET Imaging Is a Required Biomarker for Selecting Patients for Any PSMA-Targeted Therapy.
    J Nucl Med. 2021;62:1489-1491.

  15. PARKER MFL, Blecha J, Rosenberg O, Ohliger M, et al
    Cyclic (68)Ga-Labeled Peptides for Specific Detection of Human Angiotensin-Converting Enzyme 2.
    J Nucl Med. 2021;62:1631-1637.
    PubMed     Abstract available

    October 2021
  16. YUSUFALY T, Zou J, Nelson T, Williamson C, et al
    Improved Prognosis of Treatment Failure in Cervical Cancer with Non-Tumor Positron Emission Tomography / Computed Tomography Radiomics.
    J Nucl Med. 2021 Oct 28. pii: jnumed.121.262618. doi: 10.2967/jnumed.121.262618.
    PubMed     Abstract available

  17. AHLMAN MA, Maass-Moreno R, Grayson PC peter.gray
    Reply LTE, On Semi-quantitative Methods for Assessing Vascular (18)FDG-PET Activity in Large-Vessel Vasculitis.
    J Nucl Med. 2021 Oct 28. pii: jnumed.121.263158. doi: 10.2967/jnumed.121.263158.

  18. BURGGRAAFF CN, Eertink JJ, Lugtenburg PJ, Hoekstra OS, et al
    (18)F-FDG PET improves baseline clinical predictors of response in diffuse large B-cell lymphoma: The HOVON-84 study.
    J Nucl Med. 2021 Oct 21. pii: jnumed.121.262205. doi: 10.2967/jnumed.121.262205.
    PubMed     Abstract available

  19. GHEYSENS O, Belkhir L, Jamar F
    Imaging in Post-COVID Lung Disease (PCLD): does [(18)F]-FDG-PET/CT have the Key?
    J Nucl Med. 2021 Oct 21. pii: jnumed.121.263166. doi: 10.2967/jnumed.121.263166.

  20. LASNON C, Girault G, Lebtahi R, Ansquer C, et al
    Women Authors in Nuclear Medicine Journals: a Survey from 2014 to 2020.
    J Nucl Med. 2021 Oct 21. pii: jnumed.121.262773. doi: 10.2967/jnumed.121.262773.
    PubMed     Abstract available

    Perspective on Fibroblast Activation Protein Specific PET/CT Imaging in Fibrotic Interstitial Lung Diseases: Imaging Fibrosis - a New Paradigm for Molecular Imaging?
    J Nucl Med. 2021 Oct 14. pii: jnumed.121.262944. doi: 10.2967/jnumed.121.262944.

  22. SONNI I, Felker ER, Lenis AT, Sisk AE, et al
    Head-to-head comparison of (68)Ga-PSMA-11 PET/CT and mpMRI with histopathology gold-standard in the detection, intra-prostatic localization and local extension of primary prostate cancer: results from a prospective single-center imaging trial.
    J Nucl Med. 2021 Oct 14. pii: jnumed.121.262398. doi: 10.2967/jnumed.121.262398.
    PubMed     Abstract available

  23. RISCHKA L, Vraka C, Pichler V, Rasul S, et al
    First-in-human brain PET imaging of the GluN2B-containing N-methyl-D-aspartate receptor with (R)-(11)C-Me-NB1.
    J Nucl Med. 2021 Oct 7. pii: jnumed.121.262427. doi: 10.2967/jnumed.121.262427.
    PubMed     Abstract available

  24. FERDINANDUS J, Fendler WP, Farolfi A, Washington S, et al
    PSMA PET validates higher rates of metastatic disease for European Association of Urology Biochemical Recurrence Risk Groups: an international multicenter study.
    J Nucl Med. 2021 Oct 7. pii: jnumed.121.262821. doi: 10.2967/jnumed.121.262821.
    PubMed     Abstract available

  25. KESSLER L, Ferdinandus J, Hirmas N, Zarrad F, et al
    Pitfalls and common findings in (68)Ga-FAPI-PET - A pictorial analysis.
    J Nucl Med. 2021 Oct 7. pii: jnumed.121.262808. doi: 10.2967/jnumed.121.262808.
    PubMed     Abstract available

  26. MAHAJAN S, Barker CA, Mauguen A, D'Angelo SP, et al
    (18)F-FDG PET/CT for post-treatment surveillance imaging of patients with stage III Merkel cell carcinoma.
    J Nucl Med. 2021 Oct 7. pii: jnumed.121.262882. doi: 10.2967/jnumed.121.262882.
    PubMed     Abstract available

  27. BARATTO L, Hawk KE, States L, Qi J, et al
    PET/MRI Improves Management of Children with Cancer.
    J Nucl Med. 2021;62:1334-1340.
    PubMed     Abstract available

  28. JOHNSON BJ, Van Abel KM, Ma DJ, Johnson DR, et al
    (18)F-FDG-Avid Axillary Lymph Nodes After COVID-19 Vaccination.
    J Nucl Med. 2021;62:1483-1484.

    September 2021
  29. TAHERPOUR J, Jaber M, Voges B, Apostolova I, et al
    Predicting the outcome of epilepsy surgery by covariance pattern analysis of ictal perfusion SPECT.
    J Nucl Med. 2021 Sep 30. pii: jnumed.121.262702. doi: 10.2967/jnumed.121.262702.
    PubMed     Abstract available

  30. XU M, Zhang P, Ding J, Chen J, et al
    Albumin Binder-Conjugated Fibroblast Activation Protein Inhibitor Radiopharmaceuticals for Cancer Therapy.
    J Nucl Med. 2021 Sep 30. pii: jnumed.121.262533. doi: 10.2967/jnumed.121.262533.
    PubMed     Abstract available

  31. PALESTRO C, Clark A, Grady E, Heiba S, et al
    Appropriate Use Criteria for the Use of Nuclear Medicine in Musculoskeletal Infection Imaging.
    J Nucl Med. 2021 Sep 30. pii: jnumed.121.262579. doi: 10.2967/jnumed.121.262579.

  32. CROMPTON J, Armstrong WR, Eckardt MA, Seyedroudbari A, et al
    (18)F-FLT PET/CT as a prognostic imaging biomarker of disease specific survival in patients with primary soft tissue sarcoma.
    J Nucl Med. 2021 Sep 30. pii: jnumed.121.262502. doi: 10.2967/jnumed.121.262502.
    PubMed     Abstract available

  33. JADVAR H, Calais J, Fanti S, Feng F, et al
    Appropriate Use Criteria for Prostate-Specific Membrane Antigen PET Imaging.
    J Nucl Med. 2021 Sep 30. pii: jnumed.121.263262. doi: 10.2967/jnumed.121.263262.

  34. GU B, Xu X, Zhang J, Ou X, et al
    The Added Value of (68)Ga-FAPI-04 PET/CT in Patients with Head and Neck Cancer of Unknown Primary with (18)F-FDG Negative Findings.
    J Nucl Med. 2021 Sep 30. pii: jnumed.121.262790. doi: 10.2967/jnumed.121.262790.
    PubMed     Abstract available

  35. HU Y, Liu G, Yu H, Wang Y, et al
    Feasibility of ultra-low (18)F-FDG activity acquisitions using total-body PET/CT.
    J Nucl Med. 2021 Sep 30. pii: jnumed.121.262038. doi: 10.2967/jnumed.121.262038.
    PubMed     Abstract available

  36. ZHAO L, Niu B, Fang J, Pang Y, et al
    Synthesis, preclinical evaluation, and a pilot clinical PET imaging study of (68)Ga-labeled FAPI dimer.
    J Nucl Med. 2021 Sep 23. pii: jnumed.121.263016. doi: 10.2967/jnumed.121.263016.
    PubMed     Abstract available

  37. WEBER M, Schmitz J, Maric I, Pabst KM, et al
    Diagnostic performance of [(124)I]m-iodobenzylguanidine PET/CT in patients with pheochromocytoma.
    J Nucl Med. 2021 Sep 23. pii: jnumed.121.262797. doi: 10.2967/jnumed.121.262797.
    PubMed     Abstract available

  38. SONG H, Iagaru A, Rowe SP
    (18)F DCFPyL PET Acquisition, Interpretation and Reporting: Suggestions Post Food and Drug Administration Approval.
    J Nucl Med. 2021 Sep 16. pii: jnumed.121.262989. doi: 10.2967/jnumed.121.262989.
    PubMed     Abstract available

  39. NIENHUIS PH, Antunes IF, Glaudemans AWJM, Jalving M, et al
    (18)F-BMS986192 PET imaging of PD-L1 in metastatic melanoma patients with brain metastases treated with immune checkpoint inhibitors. A pilot study.
    J Nucl Med. 2021 Sep 9. pii: jnumed.121.262368. doi: 10.2967/jnumed.121.262368.
    PubMed     Abstract available

  40. ZANOVELLO M, Soraru G, Campi C, Anglani M, et al
    Brainstem glucose hypermetabolism in ALS/FTD and shorten survival: a (18)F-FDG PET/MR study.
    J Nucl Med. 2021 Sep 9. pii: jnumed.121.262232. doi: 10.2967/jnumed.121.262232.
    PubMed     Abstract available

  41. MHLANGA J, Haq A, Derenoncourt P, Bhandiwad A, et al
    (18)F-FDG Positron Emission Tomography in Myocardial Viability Assessment: A Practical and Time Efficient Protocol.
    J Nucl Med. 2021 Sep 9. pii: jnumed.121.262432. doi: 10.2967/jnumed.121.262432.
    PubMed     Abstract available

  42. LAFFON E, Marthan R
    On Semi-quantitative Methods for Assessing Vascular (18)FDG-PET Activity in Large-Vessels Vasculitis.
    J Nucl Med. 2021 Sep 2. pii: jnumed.121.263060. doi: 10.2967/jnumed.121.263060.

  43. FOURQUET A, Rosenberg A, Mena E, Shih JJ, et al
    A comparison of (18)F-DCFPyL, (18)F-NaF and (18)F-FDG PET/CT in a prospective cohort of men with metastatic prostate cancer.
    J Nucl Med. 2021 Sep 2. pii: jnumed.121.262371. doi: 10.2967/jnumed.121.262371.
    PubMed     Abstract available

  44. CARRASQUILLO JA, Chen CC, Jha A, Pacak K, et al
    Systemic Radiopharmaceutical Therapy of Pheochromocytoma and Paraganglioma.
    J Nucl Med. 2021;62:1192-1199.
    PubMed     Abstract available

    August 2021
  45. SEIFERT R, Sandach P, Kersting D, Fendler WP, et al
    Repeatability of (68)Ga-PSMA-HBED-CC PET/CT-derived total molecular tumor volume.
    J Nucl Med. 2021 Aug 26. pii: jnumed.121.262528. doi: 10.2967/jnumed.121.262528.
    PubMed     Abstract available

  46. BAG AK, Wing MN, Sabin ND, Hwang SN, et al
    [(11)C]-Methionine PET for Identification of Pediatric High-Grade Glioma Recurrence.
    J Nucl Med. 2021 Aug 26. pii: jnumed.120.261891. doi: 10.2967/jnumed.120.261891.
    PubMed     Abstract available

  47. LO AC, James LP, Prica A, Raymakers A, et al
    Positron-emission tomography-based staging is cost-effective in early-stage follicular lymphoma.
    J Nucl Med. 2021 Aug 19. pii: jnumed.121.262324. doi: 10.2967/jnumed.121.262324.
    PubMed     Abstract available

  48. FARWELL MD, Gamache RF, Babazada H, Hellmann MD, et al
    CD8-targeted PET Imaging of Tumor Infiltrating T cells in Patients with Cancer: A Phase I First-in-Human Study of (89)Zr-Df-IAB22M2C, a Radiolabeled anti-CD8 Minibody.
    J Nucl Med. 2021 Aug 19. pii: jnumed.121.262485. doi: 10.2967/jnumed.121.262485.
    PubMed     Abstract available

  49. PARIHAR AS, Schmidt LR, Dehdashti F, Wahl RL, et al
    Detection of additional primary neoplasms on (18)F-Fluciclovine PET/CT in patients with primary prostate cancer.
    J Nucl Med. 2021 Aug 19. pii: jnumed.121.262647. doi: 10.2967/jnumed.121.262647.
    PubMed     Abstract available

  50. PAQUETTE M, Espinosa-Bentancourt E, Lavallee E, Phoenix S, et al
    (18)F-4FMFES and (18)F-FDG PET/CT in ER+ endometrial carcinomas: preliminary report.
    J Nucl Med. 2021 Aug 19. pii: jnumed.121.262617. doi: 10.2967/jnumed.121.262617.
    PubMed     Abstract available

  51. MATHEY C, Keyzer C, Blocklet D, Van Simaeys G, et al
    (18)F-fluorocholine PET/CT is more sensitive than (11)C-methionine PET/CT for the localization of hyperfunctioning parathyroid tissue in primary hyperparathyroidism.
    J Nucl Med. 2021 Aug 19. pii: jnumed.121.262395. doi: 10.2967/jnumed.121.262395.
    PubMed     Abstract available

  52. SMIT J, Borm FJ, Niemeijer AN, Huisman MC, et al
    PD-L1 PET/CT imaging with radiolabeled durvalumab in patients with advanced stage non-small cell lung cancer.
    J Nucl Med. 2021 Aug 12. pii: jnumed.121.262473. doi: 10.2967/jnumed.121.262473.
    PubMed     Abstract available

    Bringing VISION to Nuclear Medicine: accelerating evidence and changing paradigms with theranostics.
    J Nucl Med. 2021 Aug 12. pii: jnumed.121.262890. doi: 10.2967/jnumed.121.262890.

  54. LANGBEIN T, Wurzer A, Gafita A, Robertson A, et al
    The Influence of Specific Activity on the Biodistribution of (18)F-rhPSMA-7.3: A Retrospective Analysis of Clinical Positron Emission Tomography Data.
    J Nucl Med. 2021 Aug 12. pii: jnumed.121.262471. doi: 10.2967/jnumed.121.262471.
    PubMed     Abstract available

  55. LU P, Benabdallah N, Jiang W, Simons BW, et al
    Blind Image Restoration Enhances Digital Autoradiographic Imaging of Radiopharmaceutical Tissue Distribution.
    J Nucl Med. 2021 Aug 12. pii: jnumed.121.262270. doi: 10.2967/jnumed.121.262270.
    PubMed     Abstract available

  56. NAGANAWA M, Nabulsi NB, Matuskey D, Henry S, et al
    Imaging pituitary vasopressin 1B receptor in humans with the novel PET radiotracer (11)C-TASP699.
    J Nucl Med. 2021 Aug 12. pii: jnumed.121.262430. doi: 10.2967/jnumed.121.262430.
    PubMed     Abstract available

  57. FENG T, Wu Y, Zhao Y, Xu T, et al
    Whole-body Parametric Imaging of FDG PET using uEXPLORER with Reduced Scan Time.
    J Nucl Med. 2021 Aug 12. pii: jnumed.120.261651. doi: 10.2967/jnumed.120.261651.
    PubMed     Abstract available

  58. STABIN MG, Wendt RE 3rd, Flux GD
    RADAR Guide: Standard Methods for Calculating Radiation Doses for Radiopharmaceuticals Part 1. Collection of Data for Radiopharmaceutical Dosimetry.
    J Nucl Med. 2021 Aug 5. pii: jnumed.120.259200. doi: 10.2967/jnumed.120.259200.
    PubMed     Abstract available

  59. STABIN MG, Wendt RE 3rd, Flux GD
    RADAR Guide: Standard Methods for Calculating Radiation Doses for Radiopharmaceuticals Part 2. Data Analysis and Dosimetry.
    J Nucl Med. 2021 Aug 5. pii: jnumed.121.262034. doi: 10.2967/jnumed.121.262034.
    PubMed     Abstract available

  60. BRENDLE C, Maier C, Bender B, Schittenhelm J, et al
    Impact of (18)F-FET PET/MR on clinical management of brain tumor patients.
    J Nucl Med. 2021 Aug 5. pii: jnumed.121.262051. doi: 10.2967/jnumed.121.262051.
    PubMed     Abstract available

  61. IAGARU A
    2021 SNMMI Highlights Lecture: General Nuclear Medicine.
    J Nucl Med. 2021;62:12N-17N.

  62. FDA Approves (18)F-DCFPyL PET Agent in Prostate Cancer.
    J Nucl Med. 2021;62:11N.

  63. FDA Approves (18)F-DCFPyL PET Agent in Prostate Cancer.
    J Nucl Med. 2021;62:11N.

  64. CZERNIN J, Calais J
    (177)Lu-PSMA617 and the VISION Trial: One of the Greatest Success Stories in the History of Nuclear Medicine.
    J Nucl Med. 2021;62:1025-1026.

    July 2021
  65. DIETLEIN F, Kobe C, Munoz Vazquez S, Fischer T, et al
    An (89)Zr-labeled PSMA tracer for PET/CT imaging of prostate cancer patients.
    J Nucl Med. 2021 Jul 29. pii: jnumed.121.262290. doi: 10.2967/jnumed.121.262290.
    PubMed     Abstract available

  66. DONG L, Su Y, Zhu Y, Markowski MC, et al
    The European Association of Urology Biochemical Recurrence Risk Groups Predict Findings on PSMA PET in Patients with Biochemically Recurrent Prostate Cancer after Radical Prostatectomy.
    J Nucl Med. 2021 Jul 29. pii: jnumed.121.262411. doi: 10.2967/jnumed.121.262411.
    PubMed     Abstract available

  67. ABGHARI-GERST M, Armstrong WR, Nguyen K, Calais J, et al
    A comprehensive assessment of (68)Ga-PSMA-11 PET in biochemically recurrent prostate cancer: Results from a prospective multi-center study in 2005 patients.
    J Nucl Med. 2021 Jul 29. pii: jnumed.121.262412. doi: 10.2967/jnumed.121.262412.
    PubMed     Abstract available

  68. ZHOU X, Jiang J, Yang X, Liu T, et al
    First-in-human evaluation of a PD-L1-binding peptide radiotracer in non-small cell lung cancer patients with PET.
    J Nucl Med. 2021 Jul 29. pii: jnumed.121.262045. doi: 10.2967/jnumed.121.262045.
    PubMed     Abstract available

  69. CATANA C, Laforest R, An H, Boada F, et al
    A Path to Qualification of PET/MR Scanners for Multicenter Brain Imaging Studies: Evaluation of MR-based Attenuation Correction Methods Using a Patient Phantom.
    J Nucl Med. 2021 Jul 22. pii: jnumed.120.261881. doi: 10.2967/jnumed.120.261881.
    PubMed     Abstract available

  70. PRENOSIL GA, Sari H, Furstner M, Afshar-Oromieh A, et al
    Performance Characteristics of the Biograph Vision Quadra PET/CT system with long axial field of view using the NEMA NU 2-2018 Standard.
    J Nucl Med. 2021 Jul 22. pii: jnumed.121.261972. doi: 10.2967/jnumed.121.261972.
    PubMed     Abstract available

  71. OREVI M, Chicheportiche A, Ben-Haim S
    Lessons learned from post-COVID-19 vaccination PET/CT studies.
    J Nucl Med. 2021 Jul 22. pii: jnumed.121.262348. doi: 10.2967/jnumed.121.262348.
    PubMed     Abstract available

  72. GANS D, Braet P, Ahmadi Bidakhvidi N, Deroose CM, et al
    (18)F-FDG PET-CT sheds a Light on a Case of Hyponatremia.
    J Nucl Med. 2021 Jul 22. pii: jnumed.121.262369. doi: 10.2967/jnumed.121.262369.
    PubMed     Abstract available

  73. ROHRICH M, Leitz D, Glatting FM, Wefers AK, et al
    Fibroblast Activation Protein specific PET/CT imaging in fibrotic interstitial lung diseases and lung cancer: a translational exploratory study.
    J Nucl Med. 2021 Jul 16. pii: jnumed.121.261925. doi: 10.2967/jnumed.121.261925.
    PubMed     Abstract available

  74. SANCHEZ-CATASUS C, Bohnen NI, D'Cruz N, Muller M, et al
    Striatal acetylcholine-dopamine imbalance in Parkinson's disease: in vivo neuroimaging study with dual-tracer PET and dopaminergic PET-informed correlational tractography.
    J Nucl Med. 2021 Jul 16. pii: jnumed.121.261939. doi: 10.2967/jnumed.121.261939.
    PubMed     Abstract available

  75. IMPERIALE A, Boursier C, Sahakian N, Ouvrard E, et al
    Values of (68)Ga-DOTATOC and Carbidopa-assisted (18)F-DOPA PET/CT for insulinoma localization.
    J Nucl Med. 2021 Jul 16. pii: jnumed.121.262401. doi: 10.2967/jnumed.121.262401.
    PubMed     Abstract available

  76. THORNTON A, Fraioli F, Wan S, Garthwaite HS, et al
    Evolution of (18)F-FDG-PET/CT findings in patients following COVID-19 pneumonia: An Initial Investigation.
    J Nucl Med. 2021 Jul 16. pii: jnumed.121.262296. doi: 10.2967/jnumed.121.262296.
    PubMed     Abstract available

  77. BENZ MR, Armstrong WR, Ceci F, Polverari G, et al
    (18)F-FDG PET/CT imaging biomarkers for early and late evaluation of response to first-line chemotherapy in patients with pancreatic ductal adenocarcinoma.
    J Nucl Med. 2021 Jul 16. pii: jnumed.121.261952. doi: 10.2967/jnumed.121.261952.
    PubMed     Abstract available

  78. NIEMEIJER AN, Oprea Lager DE, Huisman MC, Hoekstra OS, et al
    First-in-human study of (89)Zr-pembrolizumab PET/CT in patients with advanced stage non-small-cell lung cancer.
    J Nucl Med. 2021 Jul 16. pii: jnumed.121.261926. doi: 10.2967/jnumed.121.261926.
    PubMed     Abstract available

  79. READER AJ, Schramm G
    AI for PET image reconstruction.
    J Nucl Med. 2021 Jul 8. pii: jnumed.121.262303. doi: 10.2967/jnumed.121.262303.

  80. IM C, Kim H, Zaheer J, Kim JY, et al
    PET tracing of biodistribution for orally administered (64)Cu-labeled polystyrene in mice.
    J Nucl Med. 2021 Jul 2. pii: jnumed.120.256982. doi: 10.2967/jnumed.120.256982.
    PubMed     Abstract available

  81. BOSS M, Rottenburger C, Brenner W, Blankenstein O, et al
    (68)Ga-NODAGA-exendin-4 PET improves the detection of focal congenital hyperinsulinism.
    J Nucl Med. 2021 Jul 2. pii: jnumed.121.262327. doi: 10.2967/jnumed.121.262327.
    PubMed     Abstract available

  82. STATES LJ, Davis JC, Hamel SM, Becker SA, et al
    (18)F-6-Fluoro-l-Dopa PET/CT Imaging of Congenital Hyperinsulinism.
    J Nucl Med. 2021;62.
    PubMed     Abstract available

  83. WAHL R
    Nuclear Medicine Innovations: Providing Access for All.
    J Nucl Med. 2021;62:16N.

  84. MARZELLA L, Czernin J, Hope T
    Perspectives on Radiopharmaceutical Agents from the FDA: A Conversation between Lou Marzella, Johannes Czernin, and Thomas Hope.
    J Nucl Med. 2021;62:881-883.

  85. BLAZHENETS G, Schroeter N, Bormann T, Thurow J, et al
    Slow but Evident Recovery from Neocortical Dysfunction and Cognitive Impairment in a Series of Chronic COVID-19 Patients.
    J Nucl Med. 2021;62:910-915.
    PubMed     Abstract available

    June 2021
  86. BARCA C, Kiliaan AJ, Foray C, Wachsmuth L, et al
    A longitudinal PET/MR imaging study of colony stimulating factor-1 receptor-mediated microglia depletion in experimental stroke.
    J Nucl Med. 2021 Jun 24. pii: jnumed.121.262279. doi: 10.2967/jnumed.121.262279.
    PubMed     Abstract available

  87. CZERNIN J, Calais J
    (177)Lu-PSMA617 and the VISION Trial: One of the Greatest Success Stories in the History of Nuclear Medicine.
    J Nucl Med. 2021 Jun 24. pii: jnumed.121.262710. doi: 10.2967/jnumed.121.262710.

  88. MEIER SR, Sehlin D, Roshanbin S, Lim Falk V, et al
    (11)C-PIB and (124)I-antibody PET provide differing estimates of brain amyloid-beta after therapeutic intervention.
    J Nucl Med. 2021 Jun 4. pii: jnumed.121.262083. doi: 10.2967/jnumed.121.262083.
    PubMed     Abstract available

  89. WAKFIE-CORIEH CG, Ferrando-Castagnetto F, Blanes Garcia AM, Garcia-Esquinas MG, et al
    Incidental findings suggestive of COVID-19 pneumonia in oncological patients undergoing 18F-FDG PET/CT studies: association between metabolic and structural lung changes.
    J Nucl Med. 2021 Jun 4. pii: jnumed.121.261915. doi: 10.2967/jnumed.121.261915.
    PubMed     Abstract available

  90. ZHANG X, Landgraf L, Bailis N, Unger M, et al
    Image-guided High-Intensity Focused Ultrasound, A Novel Application for Interventional Nuclear Medicine?
    J Nucl Med. 2021 Jun 4. pii: jnumed.120.256230. doi: 10.2967/jnumed.120.256230.
    PubMed     Abstract available

  91. DASHORA HR, Rosenblum JS, Quinn KA, Alessi H, et al
    Comparing Semi-quantitative and Qualitative Methods of Vascular FDG-PET Activity Measurement in Large-Vessel Vasculitis.
    J Nucl Med. 2021 Jun 4. pii: jnumed.121.262326. doi: 10.2967/jnumed.121.262326.
    PubMed     Abstract available

  92. ORELLANA P, Mut F, Estrada E, Lette MM, et al
    Status of Nuclear Medicine in Latin America and the Caribbean: IAEA Analysis of Development in the Past 6 Years.
    J Nucl Med. 2021;62:23N-29N.

  93. ALLIS J, Mankoff D
    Industry Perspective on the Changing Nuclear Medicine Landscape: A Conversation Between Jonathan Allis and David Mankoff.
    J Nucl Med. 2021;62:749-751.

  94. GAN HK, Burge M, Solomon B, Lee ST, et al
    A Phase 1 and Biodistribution Study of ABT-806i, an (111)In-Radiolabeled Conjugate of the Tumor-Specific Anti-EGFR Antibody ABT-806.
    J Nucl Med. 2021;62:787-794.
    PubMed     Abstract available

  95. EBBERS SC, Barentsz MW, de Keizer B, Krijger GC, et al
    A Rapid and Safe Infusion Protocol for (177)Lu Peptide Receptor Radionuclide Therapy.
    J Nucl Med. 2021;62:816-822.
    PubMed     Abstract available

  96. ERIKSSON O, Velikyan I, Haack T, Bossart M, et al
    Imaging of the Glucagon Receptor in Subjects with Type 2 Diabetes.
    J Nucl Med. 2021;62:833-838.
    PubMed     Abstract available

    May 2021
  97. GAFITA A, Wang H, Robertson A, Armstrong WR, et al
    Tumor sink effect in (68)Ga-PSMA-11 PET: Myth or Reality?
    J Nucl Med. 2021 May 28. pii: jnumed.121.261906. doi: 10.2967/jnumed.121.261906.
    PubMed     Abstract available

  98. RAMAN F, Fang YD, Grandhi S, Murchison CF, et al
    Dynamic Amyloid PET: Relationships to Flortaucipir Tau PET Measures.
    J Nucl Med. 2021 May 28. pii: jnumed.120.254490. doi: 10.2967/jnumed.120.254490.
    PubMed     Abstract available

  99. JIN X, Wei M, Wang S, Wang G, et al
    Detecting fibroblast activation proteins in lymphoma using (68)Ga-FAPI PET/CT.
    J Nucl Med. 2021 May 28. pii: jnumed.121.262134. doi: 10.2967/jnumed.121.262134.
    PubMed     Abstract available

  100. JACENE HA, Liu M, Cheng SC, Abbott A, et al
    Imaging Androgen Receptors in Breast Cancer with (18)F-fluoro-5alpha-dihydrotestosterone-PET: A Pilot Study.
    J Nucl Med. 2021 May 28. pii: jnumed.121.262068. doi: 10.2967/jnumed.121.262068.
    PubMed     Abstract available

  101. SEBAN RD, Champion L, Muneer I, Synn S, et al
    Potential theranostic role of bone marrow glucose metabolism on baseline [18F]-FDG PET/CT in metastatic melanoma.
    J Nucl Med. 2021 May 28. pii: jnumed.121.262361. doi: 10.2967/jnumed.121.262361.

  102. KRAUS S, Dierks A, Rasche L, Kertels O, et al
    (68)Ga-Pentixafor-PET/CT imaging represents a novel approach to detect chemokine receptor CXCR4 expression in myeloproliferative neoplasms.
    J Nucl Med. 2021 May 28. pii: jnumed.121.262206. doi: 10.2967/jnumed.121.262206.
    PubMed     Abstract available

  103. MUNOZ C, Ellis S, Nekolla SG, Kunze KP, et al
    MR-guided motion-corrected PET image reconstruction for cardiac PET-MR.
    J Nucl Med. 2021 May 28. pii: jnumed.120.254235. doi: 10.2967/jnumed.120.254235.
    PubMed     Abstract available

  104. BIECHELE G, Sebastian Monasor L, Wind K, Blume T, et al
    Glitter in the Darkness? Non-fibrillar beta-amyloid Plaque Components Significantly Impact the beta-amyloid PET Signal in Mouse Models of Alzheimer's Disease.
    J Nucl Med. 2021 May 20. pii: jnumed.120.261858. doi: 10.2967/jnumed.120.261858.
    PubMed     Abstract available

  105. ZARAGORI T, Oster J, Roch V, Hossu G, et al
    (18)F-FDOPA PET for the non-invasive prediction of glioma molecular parameters: a radiomics study.
    J Nucl Med. 2021 May 20. pii: jnumed.120.261545. doi: 10.2967/jnumed.120.261545.
    PubMed     Abstract available

  106. GUBERINA M, Poettgen C, Metzenmacher M, Wiesweg M, et al
    J Nucl Med. 2021 May 20. pii: jnumed.120.260646. doi: 10.2967/jnumed.120.260646.
    PubMed     Abstract available

  107. MORAWITZ J, Bruckmann NM, Dietzel F, Ullrich T, et al
    Determining the axillary nodal status with four current imaging modalities including (18)F-FDG PET/MRI in newly diagnosed breast cancer: A comparative study using histopathology as reference standard.
    J Nucl Med. 2021 May 20. pii: jnumed.121.262009. doi: 10.2967/jnumed.121.262009.
    PubMed     Abstract available

  108. COLLET S, Guillamo JS, Berro DH, Chakhoyan A, et al
    Simultaneous mapping of vasculature, hypoxia and proliferation using DSC-MRI, (18)F-FMISO PET, and (18)F-FLT PET in relation to contrast enhancement in newly diagnosed glioblastoma.
    J Nucl Med. 2021 May 20. pii: jnumed.120.249524. doi: 10.2967/jnumed.120.249524.
    PubMed     Abstract available

  109. BARBATO F, Fendler WP, Rauscher I, Herrmann K, et al
    PSMA-PET for the assessment of metastatic hormone-sensitive prostate cancer volume of disease.
    J Nucl Med. 2021 May 14. pii: jnumed.121.262120. doi: 10.2967/jnumed.121.262120.
    PubMed     Abstract available

  110. EL-ATOUM B, Ebert M, Bucher B, Afify Z, et al
    Is (18)F-FDG PET/CT effective in identifying true residual disease after treatment of pediatric PTLD?
    J Nucl Med. 2021 May 14. pii: jnumed.121.262414. doi: 10.2967/jnumed.121.262414.

  111. BOERS J, Loudini N, Brunsch CL, Koza SA, et al
    Value of (18)F-FES-PET to solve clinical dilemmas in breast cancer patients: a retrospective study.
    J Nucl Med. 2021 May 14. pii: jnumed.120.256826. doi: 10.2967/jnumed.120.256826.
    PubMed     Abstract available

  112. HENDERSON TA, DeBruin S, Briandet P
    (18)F-FDG PET National Coverage Determination for Infection/Inflammation Retired.
    J Nucl Med. 2021;62:18N-22N.

  113. WAHL RL, Ahuja S, Clarke B
    Current Landscape of Radiopharmaceutical Therapies: SNMMI Therapy Task Force Survey.
    J Nucl Med. 2021;62:11N-16N.

  114. Challenges and Promise for Nuclear Medicine in Africa: A Conversation Between Mike Sathekge and Johannes Czernin.
    J Nucl Med. 2021;62:593-595.

  115. YOSHINAGA K, Abe T, Okamoto S, Uchiyama Y, et al
    Effects of Repeated (131)I-Meta-Iodobenzylguanidine Radiotherapy on Tumor Size and Tumor Metabolic Activity in Patients with Metastatic Neuroendocrine Tumors.
    J Nucl Med. 2021;62:685-694.
    PubMed     Abstract available

  116. NAZERI A, Crandall JP, Fraum TJ, Wahl RL, et al
    Repeatability of Radiomic Features of Brown Adipose Tissue.
    J Nucl Med. 2021;62:700-706.
    PubMed     Abstract available

  117. FENG T, Zhao Y, Shi H, Li H, et al
    Total-Body Quantitative Parametric Imaging of Early Kinetics of (18)F-FDG.
    J Nucl Med. 2021;62:738-744.
    PubMed     Abstract available

  118. SCHAEFER WM, Knollmann D, Meyer PT
    Q/V-SPECT CT in times of COVID-19: Changing the order to improve safety without sacrificing accuracy.
    J Nucl Med. 2021 May 7. pii: jnumed.120.261263. doi: 10.2967/jnumed.120.261263.

    April 2021
  119. KESSLER L, Ferdinandus J, Hirmas N, Bauer S, et al
    Ga-68-FAPI as diagnostic tool in sarcoma: Data from the FAPI-PET prospective observational trial.
    J Nucl Med. 2021 Apr 30. pii: jnumed.121.262096. doi: 10.2967/jnumed.121.262096.
    PubMed     Abstract available

  120. COHEN AS, Grudzinski J, Smith GT, Peterson TE, et al
    First-in-human PET imaging and estimated radiation dosimetry of L-[5-(11)C]-glutamine in patients with metastatic colorectal cancer.
    J Nucl Med. 2021 Apr 30. pii: jnumed.120.261594. doi: 10.2967/jnumed.120.261594.
    PubMed     Abstract available

  121. CHENG JL, Dibble EH, Baird GL, Gordon LL, et al
    Diversity, Equity, and Inclusion in Academic Nuclear Medicine: National Survey of Nuclear Medicine Residency Program Directors.
    J Nucl Med. 2021 Apr 23. pii: jnumed.120.260711. doi: 10.2967/jnumed.120.260711.
    PubMed     Abstract available

  122. KWIECINSKI J, Tzolos E, Meah M, Cadet S, et al
    Machine-learning with (18)F-sodium fluoride PET and quantitative plaque analysis on CT angiography for the future risk of myocardial infarction.
    J Nucl Med. 2021 Apr 23. pii: jnumed.121.262283. doi: 10.2967/jnumed.121.262283.
    PubMed     Abstract available

  123. FENDLER WP, Herrmann K, Eiber M
    Nuclear Medicine beyond VISION.
    J Nucl Med. 2021 Apr 23. pii: jnumed.121.262441. doi: 10.2967/jnumed.121.262441.

  124. CHEN R, Wang Y, Zhu Y, Shi Y, et al
    The added value of (18)F-FDG PET/CT compared to (68)Ga-PSMA PET/CT in patients with castration-resistant prostate cancer.
    J Nucl Med. 2021 Apr 23. pii: jnumed.121.262250. doi: 10.2967/jnumed.121.262250.
    PubMed     Abstract available

  125. EIFER M, Tau N, Alhoubani Y, Kanana N, et al
    Covid-19 mRNA Vaccination: Age and Immune Status and its Association with Axillary Lymph Node PET/CT Uptake.
    J Nucl Med. 2021 Apr 23. pii: jnumed.121.262194. doi: 10.2967/jnumed.121.262194.
    PubMed     Abstract available

  126. GHZALLY Y, Imanli H, Smith M, Mahat J, et al
    Metabolic Scar Assessment with (18)F-FDG -PET: Correlation to Ischemic VT Substrate and Successful Ablation Sites.
    J Nucl Med. 2021 Apr 23. pii: jnumed.120.246413. doi: 10.2967/jnumed.120.246413.
    PubMed     Abstract available

  127. GOGOLA A, Minhas DS, Villemagne VL, Cohen AD, et al
    Direct comparison of the tau PET tracers [(18)F]flortaucipir and [(18)F]MK-6240 in human subjects.
    J Nucl Med. 2021 Apr 16. pii: jnumed.120.254961. doi: 10.2967/jnumed.120.254961.
    PubMed     Abstract available

  128. YOUNG AJ, Pantel AR, Viswanath V, Dominguez TL, et al
    Kinetic and static analysis of poly-(adenosine diphosphate-ribose) polymerase-1 (PARP-1) targeted (18)F-FluorThanatrace ((18)F-FTT) PET images of ovarian cancer.
    J Nucl Med. 2021 Apr 16. pii: jnumed.121.261894. doi: 10.2967/jnumed.121.261894.
    PubMed     Abstract available

  129. QIN C, Shao F, Gai Y, Liu Q, et al
    (68)Ga-DOTA-FAPI-04 PET/MR in the evaluation of gastric carcinomas: comparison with (18)F-FDG PET/CT.
    J Nucl Med. 2021 Apr 16. pii: jnumed.120.258467. doi: 10.2967/jnumed.120.258467.
    PubMed     Abstract available

  130. LUKEY PT, Wilson FJ
    Quantification of the alphavbeta6 Integrin by PET/CT Imaging in the Lungs of Patients after SARS-CoV2 Infection and Comparison to Fibrotic Lungs.
    J Nucl Med. 2021 Apr 9. pii: jnumed.121.262342. doi: 10.2967/jnumed.121.262342.

  131. GUGLIELMETTI C, Levi J, Huynh TL, Tiret B, et al
    Longitudinal imaging of T-cells and inflammatory demyelination in a preclinical model of multiple sclerosis using (18)F-FAraG PET and MRI.
    J Nucl Med. 2021 Apr 9. pii: jnumed.120.259325. doi: 10.2967/jnumed.120.259325.
    PubMed     Abstract available

  132. KUO HT, Lin KS, Zhang Z, Uribe CF, et al
    (177)Lu-Labeled Albumin-Binder-Conjugated PSMA-Targeting Agents with Extremely High Tumor Uptake and Enhanced Tumor-to-Kidney Absorbed Dose Ratio.
    J Nucl Med. 2021;62:521-527.
    PubMed     Abstract available

    March 2021
  133. BATEMAN TM, Heller GV, Beanlands R, Calnon DA, et al
    Practical guide for interpreting and reporting cardiac PET measurements of myocardial blood flow: an Information Statement from the American Society of Nuclear Cardiology, and the Society of Nuclear Medicine and Molecular Imaging.
    J Nucl Med. 2021 Mar 31. pii: jnumed.121.261989. doi: 10.2967/jnumed.121.261989.

  134. BAKKER IL, Froberg AC, Busstra MB, Verzijlbergen JF, et al
    GRPr antagonist (68)Ga-SB3 PET/CT-imaging of primary prostate cancer in therapy-naive patients.
    J Nucl Med. 2021 Mar 31. pii: jnumed.120.258814. doi: 10.2967/jnumed.120.258814.
    PubMed     Abstract available

  135. MICHALSKI K, Klein C, Brueggemann T, Meyer PT, et al
    Assessing Response to [(177)Lu]PSMA Radioligand Therapy using modified PSMA PET Progression Criteria.
    J Nucl Med. 2021 Mar 31. pii: jnumed.120.260836. doi: 10.2967/jnumed.120.260836.
    PubMed     Abstract available

  136. VEAL M, Dias G, Kersemans V, Sneddon D, et al
    A Model System to Explore the Detection Limits of Antibody-Based Immuno-SPECT Imaging of Exclusively Intranuclear Epitopes.
    J Nucl Med. 2021 Mar 31. pii: jnumed.120.251173. doi: 10.2967/jnumed.120.251173.
    PubMed     Abstract available

  137. IMPERIALE A, Meuter L, Pacak K, Taieb D, et al
    Imaging of small intestine neuroendocrine neoplasms: Is SSTR PET the holy grail?
    J Nucl Med. 2021 Mar 26. pii: jnumed.121.262140. doi: 10.2967/jnumed.121.262140.

  138. BUVAT I, Orlhac F
    The T.R.U.E. checklist for identifying impactful AI-based findings in nuclear medicine: is it True? Is it Reproducible? Is it Useful? Is it Explainable?
    J Nucl Med. 2021 Mar 26. pii: jnumed.120.261586. doi: 10.2967/jnumed.120.261586.

  139. OZUTEMIZ C, Koksel Y, Froelich JW, Rubin N, et al
    J Nucl Med. 2021 Mar 26. pii: jnumed.121.261981. doi: 10.2967/jnumed.121.261981.
    PubMed     Abstract available

  140. PENG S, Tang C, Schindlbeck K, Rydzinski Y, et al
    Dynamic (18)F-FPCIT PET: Quantification of Parkinson's disease metabolic networks and nigrostriatal dopaminergic dysfunction in a single imaging session.
    J Nucl Med. 2021 Mar 19. pii: jnumed.120.257345. doi: 10.2967/jnumed.120.257345.
    PubMed     Abstract available

  141. AFAQ A, Payne H, Davda R, Hines J, et al
    A Phase II, Open-label study to assess safety and management change using (68)Ga-THP PSMA PET/CT in patients with high risk primary prostate cancer or biochemical recurrence after radical treatment: The PRONOUNCED study.
    J Nucl Med. 2021 Mar 19. pii: jnumed.120.257527. doi: 10.2967/jnumed.120.257527.
    PubMed     Abstract available

  142. NARCISO L, Ssali T, Liu L, Biernaski H, et al
    A Noninvasive Method for Quantifying Cerebral Metabolic Rate of Oxygen by Hybrid PET/MRI: Validation in a Porcine Model.
    J Nucl Med. 2021 Mar 19. pii: jnumed.120.260521. doi: 10.2967/jnumed.120.260521.
    PubMed     Abstract available

  143. BUCKNOR MD, Hope T
    Reply: "Disparities in PET imaging for prostate cancer at a tertiary academic medical center".
    J Nucl Med. 2021 Mar 19. pii: jnumed.121.262332. doi: 10.2967/jnumed.121.262332.

  144. VELLEMAN T, Kwee TC, Noordzij W, Ongena Y, et al
    The new integrated nuclear medicine and radiology residency program in the Netherlands: why do residents choose to subspecialize in nuclear medicine and why not?
    J Nucl Med. 2021 Mar 12. pii: jnumed.120.261503. doi: 10.2967/jnumed.120.261503.
    PubMed     Abstract available

  145. CZERNIN J, Herrmann K
    The disappearance act of Nuclear Medicine in the Netherlands: Just a new trick by the great Harry Houdini?
    J Nucl Med. 2021 Mar 12. pii: jnumed.121.262190. doi: 10.2967/jnumed.121.262190.

  146. FAROLFI A, Calderoni L, Mattana F, Mei R, et al
    Current and emerging clinical applications of PSMA-PET diagnostic imaging for prostate cancer.
    J Nucl Med. 2021 Mar 12. pii: jnumed.120.257238. doi: 10.2967/jnumed.120.257238.
    PubMed     Abstract available

  147. MARCHETTI L, Perrucci L, Pellegrino F, Baroni L, et al
    Diagnostic contribution of contrast-enhanced CT as compared to unenhanced low-dose CT in PET/CT staging and treatment response assessment of 18FDG-avid lymphomas: a prospective study.
    J Nucl Med. 2021 Mar 12. pii: jnumed.120.259242. doi: 10.2967/jnumed.120.259242.
    PubMed     Abstract available

  148. UPRIMNY C, Bayerschmidt S, Kroiss AS, Fritz J, et al
    Early injection of furosemide increases detection rate of local recurrence in prostate cancer patients with biochemical recurrence referred for (68)Ga-PSMA-11 PET/CT.
    J Nucl Med. 2021 Mar 12. pii: jnumed.120.261866. doi: 10.2967/jnumed.120.261866.
    PubMed     Abstract available

  149. RAUSCHER I, Karimzadeh A, Schiller K, Horn T, et al
    Detection efficacy of (18)F-rhPSMA-7.3 PET/CT and impact on patient management in patients with biochemical recurrence of prostate cancer after radical prostatectomy and prior to potential salvage treatment.
    J Nucl Med. 2021 Mar 12. pii: jnumed.120.260091. doi: 10.2967/jnumed.120.260091.
    PubMed     Abstract available

  150. ZWEZERIJNEN GJ, Eertink JJ, Burggraaff CN, Wiegers SE, et al
    Interobserver agreement in automated metabolic tumor volume measurements of Deauville score 4 and 5 lesions at interim (18)F-FDG PET in DLBCL.
    J Nucl Med. 2021 Mar 5. pii: jnumed.120.258673. doi: 10.2967/jnumed.120.258673.
    PubMed     Abstract available

  151. HOPE TA, Graces C, Calais J, Ehman E, et al
    Accuracy of (18)F-fluorocholine PET for the detection of parathyroid adenomas: prospective single center study.
    J Nucl Med. 2021 Mar 5. pii: jnumed.120.256735. doi: 10.2967/jnumed.120.256735.
    PubMed     Abstract available

  152. BARATTO L, Song H, Duan H, Hatami N, et al
    PSMA- and GRPR-targeted PET: Results from 50 Patients with Biochemically Recurrent Prostate Cancer.
    J Nucl Med. 2021 Mar 5. pii: jnumed.120.259630. doi: 10.2967/jnumed.120.259630.
    PubMed     Abstract available

  153. WU H, Czernin J
    A Conversation Between Hong Wu and Johannes Czernin.
    J Nucl Med. 2021;62:293-295.

  154. LODGE MA
    Phantom Preparation Using a Dilution Technique.
    J Nucl Med. 2021;62:303.

  155. ALBRECHT J, Exner S, Grotzinger C, Prasad S, et al
    Multimodal Imaging of 2-Cycle PRRT with (177)Lu-DOTA-JR11 and (177)Lu-DOTATOC in an Orthotopic Neuroendocrine Xenograft Tumor Mouse Model.
    J Nucl Med. 2021;62:393-398.
    PubMed     Abstract available

  156. BARRINGTON SF, Zwezerijnen BGJC, de Vet HCW, Heymans MW, et al
    Automated Segmentation of Baseline Metabolic Total Tumor Burden in Diffuse Large B-Cell Lymphoma: Which Method Is Most Successful? A Study on Behalf of the PETRA Consortium.
    J Nucl Med. 2021;62:332-337.
    PubMed     Abstract available

  157. PEREIRA PMR, Norfleet J, Lewis JS, Escorcia FE, et al
    Immuno-PET Detects Changes in Multi-RTK Tumor Cell Expression Levels in Response to Targeted Kinase Inhibition.
    J Nucl Med. 2021;62:366-371.
    PubMed     Abstract available

    February 2021
  158. CARLSEN EA, Johnbeck CB, Loft M, Pfeifer A, et al
    Semi-automatic tumor delineation for evaluation of (64)Cu-DOTATATE PET/CT in patients with neuroendocrine neoplasms: prognostication based on lowest lesion uptake and total tumor volume.
    J Nucl Med. 2021 Feb 26. pii: jnumed.120.258392. doi: 10.2967/jnumed.120.258392.
    PubMed     Abstract available

  159. LAFFON E, Marthan R
    Specific and Non-Specific Uptake in Quantitative (89)Zr-Immuno-PET.
    J Nucl Med. 2021 Feb 26. pii: jnumed.121.262065. doi: 10.2967/jnumed.121.262065.

  160. YANG J, Shi L, Wang R, Miller EJ, et al
    Direct Attenuation Correction Using Deep Learning for Cardiac SPECT: A Feasibility Study.
    J Nucl Med. 2021 Feb 26. pii: jnumed.120.256396. doi: 10.2967/jnumed.120.256396.
    PubMed     Abstract available

  161. DI CARLI MF
    Hot Topic, Why will PET be the future of nuclear cardiology?
    J Nucl Med. 2021 Feb 19. pii: jnumed.120.254979. doi: 10.2967/jnumed.120.254979.

  162. VERHAGEN MV, Menezes LJ, Neriman D, Watson TA, et al
    (18)F-FDG PET/MRI for staging and interim response assessment in pediatric and adolescent Hodgkin lymphoma: a prospective study with (18)F-FDG PET/CT as reference standard.
    J Nucl Med. 2021 Feb 19. pii: jnumed.120.260059. doi: 10.2967/jnumed.120.260059.
    PubMed     Abstract available

  163. ZUKOTYNSKI KA, Emmenegger U, Hotte S, Kapoor A, et al
    Prospective, Single-Arm Trial Evaluating Changes in Uptake Patterns on Prostate-Specific Membrane Antigen (PSMA)-Targeted (18)F-DCFPyL PET/CT in Patients with Castration-Resistant Prostate Cancer Starting Abiraterone or Enzalutamide.
    J Nucl Med. 2021 Feb 19. pii: jnumed.120.259069. doi: 10.2967/jnumed.120.259069.
    PubMed     Abstract available

  164. CHAN DL, Ulaner GA, Pattison DA, Wyld D, et al
    Dual Positron Emission Tomography imaging in bronchial neuroendocrine neoplasms (NENs): The NETPET score as a prognostic biomarker.
    J Nucl Med. 2021 Feb 12. pii: jnumed.120.257659. doi: 10.2967/jnumed.120.257659.
    PubMed     Abstract available

  165. BARRET O, Zhang L, Alagille D, Constantinescu CC, et al
    Dopamine D1 Receptor Agonist PET Tracer Development: Assessment in Non-Human Primates.
    J Nucl Med. 2021 Feb 12. pii: jnumed.120.256008. doi: 10.2967/jnumed.120.256008.
    PubMed     Abstract available

  166. ORTEGA C, Wong RK, Schaefferkoetter J, Veit-Haibach P, et al
    Quantitative (68)Ga-DOTATATE PET/CT parameters for the prediction of therapy response in patients with progressive metastatic neuroendocrine tumors treated with (177)Lu-DOTATATE.
    J Nucl Med. 2021 Feb 12. pii: jnumed.120.256727. doi: 10.2967/jnumed.120.256727.
    PubMed     Abstract available

  167. DUELL J, Krummenast F, Schirbel A, Klassen P, et al
    Improved primary staging of marginal zone lymphoma by addition of CXCR4-directed PET/CT.
    J Nucl Med. 2021 Feb 12. pii: jnumed.120.257279. doi: 10.2967/jnumed.120.257279.
    PubMed     Abstract available

  168. MARIANI G, Tonaccehra M, Grosso M, Fiore E, et al
    The Role of Nuclear Medicine in the Clinical Management of Benign Thyroid Disorders. Part 2. Nodular Goiter, Hypothyroidism, and Subacute Thyroiditis.
    J Nucl Med. 2021 Feb 12. pii: jnumed.120.251504. doi: 10.2967/jnumed.120.251504.
    PubMed     Abstract available

  169. ALBERTS I, Huenermund JN, Sachpekidis C, Zacho HD, et al
    Combination of forced diuresis with additional late imaging in (68)Ga-PSMA-11 PET/CT - effects on lesion visibility and radiotracer uptake.
    J Nucl Med. 2021 Feb 5. pii: jnumed.120.257741. doi: 10.2967/jnumed.120.257741.
    PubMed     Abstract available

  170. BODET-MILIN C, Faivre-Chauvet A, Carlier T, Ansquer C, et al
    Anti-CEA pretargeted Immuno-PET shows higher sensitivity than DOPA-PET/CT to detect relapsing metastatic medullary thyroid carcinoma: Post- hoc analysis of the iPET-MTC study.
    J Nucl Med. 2021 Feb 5. pii: jnumed.120.252791. doi: 10.2967/jnumed.120.252791.
    PubMed     Abstract available

  171. WONDERGEM M, van der Zant FM, Broos WA, Knol RJ, et al
    Matched-pair comparison of (18)F-DCFPyL PET/CT and (18)F-PSMA-1007 PET/CT in 240 prostate cancer patients; inter-reader agreement and lesion detection rate of suspected lesions.
    J Nucl Med. 2021 Feb 5. pii: jnumed.120.258574. doi: 10.2967/jnumed.120.258574.
    PubMed     Abstract available

  172. NAKAMOTO R, Zaba LC, Liang T, Reddy SA, et al
    Prognostic value of bone marrow metabolism on pretreatment (18)F-FDG PET/CT in patients with metastatic melanoma treated with anti-PD-1 therapy.
    J Nucl Med. 2021 Feb 5. pii: jnumed.120.254482. doi: 10.2967/jnumed.120.254482.
    PubMed     Abstract available

  173. WAHL RL
    SNMMI Leadership Update: Advancing Radiopharmaceutical Therapy.
    J Nucl Med. 2021;62:20N.

  174. FDA Approves First PSMA-Targeted PET Drug.
    J Nucl Med. 2021;62:11N.

  175. SARTOR O, Hope TA, Calais J, Fendler WP, et al
    Oliver Sartor Talks with Thomas A. Hope, Jeremie Calais, and Wolfgang P. Fendler About FDA Approval of PSMA.
    J Nucl Med. 2021;62:146-148.

  176. CARLUCCI G, Ippisch R, Slavik R, Mishoe A, et al
    (68)Ga-PSMA-11 NDA Approval: A Novel and Successful Academic Partnership.
    J Nucl Med. 2021;62:149-155.
    PubMed     Abstract available

  177. ZANOTTI-FREGONARA P, Lammertsma AA, Innis RB
    (11)C Dosimetry Scans Should Be Abandoned.
    J Nucl Med. 2021;62:158-159.

  178. ALTMANN A, Haberkorn U, Siveke J
    The Latest Developments in Imaging of Fibroblast Activation Protein.
    J Nucl Med. 2021;62:160-167.
    PubMed     Abstract available

  179. SLOMKA PJ, Moody JB, Miller RJH, Renaud JM, et al
    Quantitative clinical nuclear cardiology, part 2: Evolving/emerging applications.
    J Nucl Med. 2021;62:168-176.
    PubMed     Abstract available

  180. AHMED H, Wallimann R, Haider A, Hosseini V, et al
    Preclinical Development of (18)F-OF-NB1 for Imaging GluN2B-Containing N-Methyl-d-Aspartate Receptors and Its Utility as a Biomarker for Amyotrophic Lateral Sclerosis.
    J Nucl Med. 2021;62:259-265.
    PubMed     Abstract available

  181. HADDAD J, Latoche JD, Nigam S, Bellavia MC, et al
    Molecular Imaging of Very Late Antigen-4 in Acute Lung Injury.
    J Nucl Med. 2021;62:280-286.
    PubMed     Abstract available

    January 2021
  182. SCHILHAM MG, Zamecnik P, Prive BM, Israel B, et al
    Head-to-head comparison of (68)Ga-prostate-specific membrane antigen PET/CT and ferumoxtran-10 enhanced MRI for the diagnosis of lymph node metastases in prostate cancer patients.
    J Nucl Med. 2021 Jan 30. pii: jnumed.120.258541. doi: 10.2967/jnumed.120.258541.
    PubMed     Abstract available

  183. WHITTINGTON A, Gunn R
    TauIQ - A canonical image based algorithm to quantify tau PET scans.
    J Nucl Med. 2021 Jan 30. pii: jnumed.120.258962. doi: 10.2967/jnumed.120.258962.
    PubMed     Abstract available

  184. F ANTUNES I, Dost R, Hoving HD, Waarde AV, et al
    Synthesis and evaluation of (18)F-enzalutamide, a new radioligand for PET Imaging of Androgen Receptors: A comparison with 16beta-(18)F-fluoro-5alpha-dihydrotestosterone.
    J Nucl Med. 2021 Jan 30. pii: jnumed.120.253641. doi: 10.2967/jnumed.120.253641.
    PubMed     Abstract available

  185. ROBU S, Richter A, Gosmann D, Seidl C, et al
    Synthesis and Preclinical Evaluation of (68)Ga-labeled Adnectin, (68)Ga-BMS-986192 as a PET Agent for Imaging PD-L1 Expression.
    J Nucl Med. 2021 Jan 30. pii: jnumed.120.258384. doi: 10.2967/jnumed.120.258384.
    PubMed     Abstract available

  186. ABIODUN-OJO OA, Jani AB, Akintayo AA, Akin-Akintayo OO, et al
    Salvage Radiotherapy Management Decision in Post-prostatectomy Patients with Recurrent Prostate Cancer Based on (18)F-Fluciclovine PET/CT Guidance.
    J Nucl Med. 2021 Jan 30. pii: jnumed.120.256784. doi: 10.2967/jnumed.120.256784.
    PubMed     Abstract available

  187. WEISSINGER M, Taran FA, Gatidis S, Kommoss S, et al
    Lymph node staging with a combined protocol of (18)F-FDG PET/MRI and sentinel node SPECT/CT: a prospective study in patients with FIGO I/II cervical carcinoma.
    J Nucl Med. 2021 Jan 28. pii: jnumed.120.255919. doi: 10.2967/jnumed.120.255919.
    PubMed     Abstract available

  188. HIRMAS N, Leyh C, Sraieb M, Barbato F, et al
    [(68)Ga]Ga-PSMA-11 PET/CT improves tumor detection and impacts management in patients with hepatocellular carcinoma (HCC).
    J Nucl Med. 2021 Jan 28. pii: jnumed.120.257915. doi: 10.2967/jnumed.120.257915.
    PubMed     Abstract available

  189. KESNER AL
    The Evolution of PET/MR is Hindered by our Field's Reluctance to Provide Critical Evaluation.
    J Nucl Med. 2021 Jan 15. pii: jnumed.120.260950. doi: 10.2967/jnumed.120.260950.

  190. GUZIK P, Fang HY, Deberle LM, Benesova M, et al
    Identification of a PET Radiotracer for Imaging of the Folate Receptor-alpha - A Potential Tool to Select Patients for Targeted Tumor Therapy.
    J Nucl Med. 2021 Jan 15. pii: jnumed.120.255760. doi: 10.2967/jnumed.120.255760.
    PubMed     Abstract available

    J Nucl Med. 2021 Jan 15. pii: jnumed.120.256081. doi: 10.2967/jnumed.120.256081.
    PubMed     Abstract available

  192. WHITMAN J, Allen IE, Bergsland EK, Suh IA, et al
    Assessment and comparison of fluorocholine PET and sestamibi scans in identifying parathyroid adenomas: a meta-analysis.
    J Nucl Med. 2021 Jan 15. pii: jnumed.120.257303. doi: 10.2967/jnumed.120.257303.
    PubMed     Abstract available

  193. MARKOWSKI MC, Velho PI, Eisenberger MA, Pomper MG, et al
    Detection of Early Progression with (18)F-DCFPyL PET/CT in Men with Metastatic Castration-Resistant Prostate Cancer Receiving Bipolar Androgen Therapy.
    J Nucl Med. 2021 Jan 15. pii: jnumed.120.259226. doi: 10.2967/jnumed.120.259226.
    PubMed     Abstract available

  194. WIBMER AG, Morris MJ, Gonen M, Zheng J, et al
    J Nucl Med. 2021 Jan 8. pii: jnumed.120.256602. doi: 10.2967/jnumed.120.256602.
    PubMed     Abstract available

  195. Humana Decision to Deny PET/CT Coverage.
    J Nucl Med. 2021;62:20N.

  196. VALI R, Alessio A, Balza R, Borgwardt L, et al
    SNMMI Procedure Standard/EANM Practice Guideline on Pediatric (18)F-FDG PET/CT for Oncology 1.0.
    J Nucl Med. 2021;62:99-110.
    PubMed     Abstract available

  197. WAHL RL, Chareonthaitawee P, Clarke B, Drzezga A, et al
    Mars Shot for Nuclear Medicine, Molecular Imaging, and Molecularly Targeted Radiopharmaceutical Therapy.
    J Nucl Med. 2021;62:6-14.
    PubMed     Abstract available

  198. CZERNIN J, Iagaru A
    Humana and (18)F-FDG PET/CT: Another Sequel to the Injustice of Being Judged by the Errors of Others.
    J Nucl Med. 2021;62:1-2.

  199. LAFFON E, Marthan R
    Distribution Volume of (18)F-BMS-986192 in NSCLC Patients.
    J Nucl Med. 2021;62:144.

  200. BUVAT I, Herrmann K, Stremitzer A, Tobia K, et al
    Irene Buvat and Ken Herrmann Talk with Alexander Stremitzer, Kevin Tobia, and Aileen Nielsen.
    J Nucl Med. 2021;62:3-5.

  201. PRICE WN 2ND, Gerke S, Cohen IG
    How Much Can Potential Jurors Tell Us About Liability for Medical Artificial Intelligence?
    J Nucl Med. 2021;62:15-16.

  202. TOBIA K, Nielsen A, Stremitzer A
    When Does Physician Use of AI Increase Liability?
    J Nucl Med. 2021;62:17-21.
    PubMed     Abstract available

  203. CAPOBIANCO N, Meignan M, Cottereau AS, Vercellino L, et al
    Deep-Learning (18)F-FDG Uptake Classification Enables Total Metabolic Tumor Volume Estimation in Diffuse Large B-Cell Lymphoma.
    J Nucl Med. 2021;62:30-36.
    PubMed     Abstract available

  204. ZIESSMAN HA, Jeyasingam M, Khan AU, McMahan Z, et al
    Experience with Esophagogastrointestinal Transit Scintigraphy in the Initial 229 Patients: Multiple Regions of Dysmotility Are Common.
    J Nucl Med. 2021;62:115-122.
    PubMed     Abstract available

    December 2020
  205. FRANCIS R, Bailey D, Hofman MS, Scott A, et al
    The Australasian Radiopharmaceutical Trials Network (ARTnet) - Clinical Trials, Evidence and Opportunity.
    J Nucl Med. 2020 Dec 31. pii: jnumed.120.258152. doi: 10.2967/jnumed.120.258152.

  206. CERCI JJ, Bogoni M, Cerci RJ, Masukawa M, et al
    PET/CT guided biopsy of suspected lung lesions requires less rebiopsy than CT guided biopsy due to inconclusive results.
    J Nucl Med. 2020 Dec 31. pii: jnumed.120.252403. doi: 10.2967/jnumed.120.252403.
    PubMed     Abstract available

  207. WALKER MD, Bradley KM, McGowan DR
    Data-Driven Respiratory Motion Correction in Clinical PET - A Turning Point.
    J Nucl Med. 2020 Dec 18. pii: jnumed.120.257022. doi: 10.2967/jnumed.120.257022.

  208. GOTO T, Kikuchi S, Mori K, Nakayama T, et al
    Cardiac Beta-Adrenergic Receptor Downregulation, Evaluated by Cardiac Positron Emission Tomography, in Chronotropic Incompetence.
    J Nucl Med. 2020 Dec 18. pii: jnumed.120.253419. doi: 10.2967/jnumed.120.253419.
    PubMed     Abstract available

  209. DEVASIA T, Dewaraja YK, Frey KA, Wong KK, et al
    A novel time-activity information sharing approach using nonlinear mixed models for patient-specific dosimetry with reduced imaging time points: application in SPECT/CT imaging post-(177)Lu-DOTATATE.
    J Nucl Med. 2020 Dec 18. pii: jnumed.120.256255. doi: 10.2967/jnumed.120.256255.
    PubMed     Abstract available

  210. WANG C, Leach BI, Lister D, Adams SR, et al
    Metallo-Fluorocarbon Nanoemulsion for Inflammatory Macrophage Detection via PET and MRI.
    J Nucl Med. 2020 Dec 4. pii: jnumed.120.255273. doi: 10.2967/jnumed.120.255273.
    PubMed     Abstract available

  211. HICKS RJ, Roselt PJ, Kallur KG, Tothill RW, et al
    State-of-the-Art: FAPI PET/CT-Will it end the hegemony of FDG in oncology?
    J Nucl Med. 2020 Dec 4. pii: jnumed.120.256271. doi: 10.2967/jnumed.120.256271.
    PubMed     Abstract available

  212. RONCALI E, Capala J, Benedict SH, Akabani G, et al
    Overview of the First NRG-NCI Workshop on Dosimetry of Systemic Radiopharmaceutical Therapy (RPT).
    J Nucl Med. 2020 Dec 4. pii: jnumed.120.255547. doi: 10.2967/jnumed.120.255547.
    PubMed     Abstract available

  213. VAN DONGEN GAMS, Beaino W, Windhorst AD, Zwezerijnen GJC, et al
    The navigating and de-risking role of (89)Zr-immuno-PET in the development of biopharmaceuticals.
    J Nucl Med. 2020 Dec 4. pii: jnumed.119.239558. doi: 10.2967/jnumed.119.239558.
    PubMed     Abstract available

  214. KROENKE M, Mirzoyan L, Horn T, Peeken JC, et al
    Matched-pair comparison of (68)Ga-PSMA-11 and (18)F-rhPSMA-7 PET/CT in patients with primary and biochemical recurrence of prostate cancer: frequency of non-tumor related uptake and tumor positivity.
    J Nucl Med. 2020 Dec 4. pii: jnumed.120.251447. doi: 10.2967/jnumed.120.251447.
    PubMed     Abstract available

  215. TANNER JA, Rabinovici GD
    Relationship Between Tau and Cognition in the Evolution of Alzheimer's Disease: New Insights from Tau PET.
    J Nucl Med. 2020 Dec 4. pii: jnumed.120.257824. doi: 10.2967/jnumed.120.257824.

  216. HOPE TA
    Updates to the Appropriate-Use Criteria for Somatostatin Receptor PET.
    J Nucl Med. 2020;61:1764.

  217. CARSON RE
    Quantitative Cerebral Blood Flow with PET in the 1980s: Going with the Flow.
    J Nucl Med. 2020;61.

  218. WEBER WA, Czernin J, Anderson CJ, Badawi RD, et al
    The Future of Nuclear Medicine, Molecular Imaging, and Theranostics.
    J Nucl Med. 2020;61.

  219. CATANA C
    A Stepping-Stone to Fully Integrated Whole-Body PET/MRI.
    J Nucl Med. 2020;61.

  220. BARTHEL H
    Switching on Brain PET to Light Up Amyloid Pathology In Vivo.
    J Nucl Med. 2020;61.

  221. The 60th Anniversary Issue of The Journal of Nuclear Medicine.
    J Nucl Med. 2020;61.

  222. PAGANELLI G, Matteucci F
    Importance of PET with (68)Ga-Labeled Somatostatin Analogs.
    J Nucl Med. 2020;61.

  223. STUSCHKE M, Pottgen C
    (18)F-FDG PET/CT for Target Volume Contouring in Lung Cancer Radiotherapy.
    J Nucl Med. 2020;61.

  224. TAI YC
    Small-Animal PET: A Technology That Changed Our Field.
    J Nucl Med. 2020;61.

  225. FOWLER JS
    (18)F-FDG Radiosynthesis: A Landmark in the History of PET.
    J Nucl Med. 2020;61.

  226. POLVOY I, Flavell RR, Rosenberg OS, Ohliger MA, et al
    Nuclear Imaging of Bacterial Infection: The State of the Art and Future Directions.
    J Nucl Med. 2020;61:1708-1716.
    PubMed     Abstract available

  227. A Conversation Between Frans van Houten and Ken Herrmann.
    J Nucl Med. 2020;61:1697-1700.

  228. CULLINANE C, Jeffery CM, Roselt PD, van Dam EM, et al
    Peptide Receptor Radionuclide Therapy with (67)Cu-CuSarTATE Is Highly Efficacious Against a Somatostatin-Positive Neuroendocrine Tumor Model.
    J Nucl Med. 2020;61:1800-1805.
    PubMed     Abstract available

  229. SACHER C, Blume T, Beyer L, Biechele G, et al
    Asymmetry of Fibrillar Plaque Burden in Amyloid Mouse Models.
    J Nucl Med. 2020;61:1825-1831.
    PubMed     Abstract available

  230. TOMS J, Kogler J, Maschauer S, Daniel C, et al
    Targeting Fibroblast Activation Protein: Radiosynthesis and Preclinical Evaluation of an (18)F-Labeled FAP Inhibitor.
    J Nucl Med. 2020;61:1806-1813.
    PubMed     Abstract available

  231. BERMAN DS, Rozanski A
    Pharmacologic Stress Testing: Its Roots, Its Impact, and Its Future.
    J Nucl Med. 2020;61.

  232. HOFMAN MS
    Prostate-Specific Membrane Antigen: The Target of the Decade, from Biochemical Recurrence to Widespread Adoption.
    J Nucl Med. 2020;61.

    Establishing a Clinical Role for Bone Scans.
    J Nucl Med. 2020;61.

  234. HICKS RJ, Hoekstra OS
    PERCISTence: Strength or Stubbornness?
    J Nucl Med. 2020;61.

    On the Origin of Hybrid Imaging.
    J Nucl Med. 2020;61.

  236. BODEI L
    Somatostatin Receptor Scintigraphy: Blazing in Indium and Quenching in Gallium.
    J Nucl Med. 2020;61.

    From (201)Tl to (99m)Tc-Sestamibi.
    J Nucl Med. 2020;61.

    November 2020
  238. SHIYAM SUNDAR LK, Iommi D, Muzik O, Chalampalakis Z, et al
    Conditional Generative Adversarial Networks (cGANs) aided motion correction of dynamic (18)F-FDG PET brain studies.
    J Nucl Med. 2020 Nov 27. pii: jnumed.120.248856. doi: 10.2967/jnumed.120.248856.
    PubMed     Abstract available

  239. ZHAO N, Huang Y, Wang YH, Muir RK, et al
    Ferronostics: Measuring Tumoral Ferrous Iron with PET to Predict Sensitivity to Iron-Targeted Cancer Therapies.
    J Nucl Med. 2020 Nov 27. pii: jnumed.120.252460. doi: 10.2967/jnumed.120.252460.
    PubMed     Abstract available

  240. PACKARD RRS, Lazewatsky JL, Orlandi C, Maddahi J, et al
    Diagnostic Performance of PET vs. SPECT Myocardial Perfusion Imaging in Patients with Smaller Left Ventricles: a Substudy of the (18)F-Flurpiridaz Phase-III Clinical Trial.
    J Nucl Med. 2020 Nov 27. pii: jnumed.120.252007. doi: 10.2967/jnumed.120.252007.
    PubMed     Abstract available

  241. BOURLA AB, Herrmann K
    Real-World Data as an Evidence Source in Nuclear Medicine.
    J Nucl Med. 2020 Nov 27. pii: jnumed.120.258665. doi: 10.2967/jnumed.120.258665.

  242. RAY S, Lisok A, Minn IL, Josefsson A, et al
    Preclinical evaluation of (213)Bi-/(225)Ac-labeled low-molecular-weight compounds for radiopharmaceutical therapy of prostate cancer.
    J Nucl Med. 2020 Nov 27. pii: jnumed.120.256388. doi: 10.2967/jnumed.120.256388.
    PubMed     Abstract available

  243. KURCH L, Andreas H, Georgi TW, Rekowski J, et al
    Interim positron emission tomography in diffuse large B-cell lymphoma.
    J Nucl Med. 2020 Nov 27. pii: jnumed.120.255034. doi: 10.2967/jnumed.120.255034.
    PubMed     Abstract available

  244. CZERNIN J, Iagaru A
    Humana and (18)F-FDG PET/CT: Another Sequel to the Injustice of Being Judged by the Errors of Others.
    J Nucl Med. 2020 Nov 13. pii: jnumed.120.260208. doi: 10.2967/jnumed.120.260208.

  245. CHANTADISAI M, Buschner G, Kronke M, Rauscher I, et al
    Positive predictive value and correct detection rate of (18)F-rhPSMA-7 PET in biochemically recurrent prostate cancer validated by composite reference standard.
    J Nucl Med. 2020 Nov 13. pii: jnumed.120.255661. doi: 10.2967/jnumed.120.255661.
    PubMed     Abstract available

  246. CECCON G, Lohmann P, Werner JM, Tscherpel C, et al
    Early treatment response assessment using (18)F-FET PET compared to contrast-enhanced MRI in glioma patients following adjuvant temozolomide chemotherapy.
    J Nucl Med. 2020 Nov 6. pii: jnumed.120.254243. doi: 10.2967/jnumed.120.254243.
    PubMed     Abstract available

  247. LEVI J, Goth S, Huynh L, Lam T, et al
    (18)F-FAraG PET for CD8 Profiling of Tumors and Assessment of Immunomodulation by Chemotherapy.
    J Nucl Med. 2020 Nov 6. pii: jnumed.120.249078. doi: 10.2967/jnumed.120.249078.
    PubMed     Abstract available

  248. MEIJER D, Donswijk ML, Bodar YJL, van Leeuwen PJ, et al
    Biochemical Persistence of Prostate-specific Antigen after Robot-assisted Laparoscopic Radical Prostatectomy: Tumor localizations using PSMA PET/CT imaging.
    J Nucl Med. 2020 Nov 6. pii: jnumed.120.252528. doi: 10.2967/jnumed.120.252528.
    PubMed     Abstract available

  249. TOWNSEND D, Beyer T, Czernin J
    20 Years of PET/CT: A Conversation with David Townsend and Thomas Beyer.
    J Nucl Med. 2020;61:1541-1543.

  250. CARTER LM, Henry KE, Platzman A, Lewis JS, et al
    3D-Printable Platform for High-Throughput Small-Animal Imaging.
    J Nucl Med. 2020;61:1691-1692.

  251. MAIRINGER S, Sake JA, Hernandez Lozano I, Filip T, et al
    Assessing the Activity of Multidrug Resistance-Associated Protein 1 at the Lung Epithelial Barrier.
    J Nucl Med. 2020;61:1650-1657.
    PubMed     Abstract available

  252. SUURS FV, Lorenczewski G, Stienen S, Friedrich M, et al
    The Biodistribution of a CD3 and EpCAM Bispecific T-Cell Engager Is Driven by the CD3 Arm.
    J Nucl Med. 2020;61:1594-1601.
    PubMed     Abstract available

    October 2020
  253. HOU X, Brosch J, Uribe C, Desy A, et al
    Feasibility of single-time-point dosimetry for radiopharmaceutical therapies.
    J Nucl Med. 2020 Oct 30. pii: jnumed.120.254656. doi: 10.2967/jnumed.120.254656.
    PubMed     Abstract available

  254. KOSTYSZYN D, Fechter T, Bartl N, Grosu AL, et al
    Intraprostatic Tumour Segmentation on PSMA-PET Images in Patients with Primary Prostate Cancer with a Convolutional Neural Network.
    J Nucl Med. 2020 Oct 30. pii: jnumed.120.254623. doi: 10.2967/jnumed.120.254623.
    PubMed     Abstract available

  255. FRANC BL, Iagaru A
    Letter to the Editor: "Disparities in PET imaging for prostate cancer at a tertiary academic medical center".
    J Nucl Med. 2020 Oct 30. pii: jnumed.120.258160. doi: 10.2967/jnumed.120.258160.

  256. ALUICIO-SARDUY E, Barnhart TE, Weichert J, Hernandez R, et al
    Cyclotron produced (132)La as a PET imaging surrogate of therapeutic (225)Ac.
    J Nucl Med. 2020 Oct 30. pii: jnumed.120.255794. doi: 10.2967/jnumed.120.255794.
    PubMed     Abstract available

  257. MAMMATAS LH, Yaqub M, Hendrikse NH, Hoekstra OS, et al
    (11)C-sorafenib and (15)O-H2O PET for early evaluation of sorafenib therapy.
    J Nucl Med. 2020 Oct 30. pii: jnumed.120.251611. doi: 10.2967/jnumed.120.251611.
    PubMed     Abstract available

  258. ROHRICH M, Naumann P, Giesel FL, Choyke P, et al
    Impact of (68)Ga-FAPI-PET/CT imaging on the therapeutic management of primary and recurrent pancreatic ductal adenocarcinomas.
    J Nucl Med. 2020 Oct 23. pii: jnumed.120.253062. doi: 10.2967/jnumed.120.253062.
    PubMed     Abstract available

  259. BLAZHENETS G, Frings L, Sorensen A, Meyer PT, et al
    Principal components analysis based measures of PET data closely reflect neuropathological staging schemes.
    J Nucl Med. 2020 Oct 23. pii: jnumed.120.252783. doi: 10.2967/jnumed.120.252783.
    PubMed     Abstract available

  260. GOLAN S, Aviv T, Groshar D, Yakimov M, et al
    Dynamic (68)Ga-PSMA-11 PET/CT for the primary evaluation of localized renal mass: a prospective study.
    J Nucl Med. 2020 Oct 23. pii: jnumed.120.251272. doi: 10.2967/jnumed.120.251272.
    PubMed     Abstract available

  261. BINDERUP T, Knigge U, Johnbeck CB, Loft A, et al
    (18)F-FDG-PET is superior to WHO grading as prognostic tool in neuroendocrine neoplasms and useful in guiding peptide receptor radionuclide therapy: a prospective 10-year follow-up study of 166 patients.
    J Nucl Med. 2020 Oct 16. pii: jnumed.120.244798. doi: 10.2967/jnumed.120.244798.
    PubMed     Abstract available

  262. GERARD SK
    PET/MRI versus PET/CT for Whole-Body Staging.
    J Nucl Med. 2020 Oct 9. pii: jnumed.120.256453. doi: 10.2967/jnumed.120.256453.

  263. CHRISTENSEN TN, Langer SW, Persson GF, Larsen KR, et al
    (18)F-FLT-PET/CT adds value to (18)F-FDG-PET/CT for diagnosing relapse after definitive radiotherapy in patients with lung cancer. Results of a prospective clinical trial.
    J Nucl Med. 2020 Oct 9. pii: jnumed.120.247742. doi: 10.2967/jnumed.120.247742.
    PubMed     Abstract available

  264. LODGE MA, Lesniak W, Gorin MA, Pienta KJ, et al
    Measurement of PET Quantitative Bias In Vivo.
    J Nucl Med. 2020 Oct 9. pii: jnumed.120.251397. doi: 10.2967/jnumed.120.251397.
    PubMed     Abstract available

  265. PRIOR JO, Mirzaei S, Gnesin S, Nicod Lalonde M, et al
    Dose optimization in pediatric studies: Why this is important and can benefit every nuclear medicine department.
    J Nucl Med. 2020 Oct 9. pii: jnumed.120.254193. doi: 10.2967/jnumed.120.254193.

  266. VIDAL-SICART S, Rioja ME, Prieto A, Goni E, et al
    Sentinel Lymph Node Biopsy in breast cancer with (99m)Tc-Tilmanocept: A novel tracer in the real life. A multicenter study.
    J Nucl Med. 2020 Oct 9. pii: jnumed.120.252064. doi: 10.2967/jnumed.120.252064.
    PubMed     Abstract available

  267. SPENCER BA, Berg E, Schmall JP, Omidvari N, et al
    Performance evaluation of the uEXPLORER Total-body PET/CT scanner based on NEMA NU 2-2018 with additional tests to characterize long axial field-of-view PET scanners.
    J Nucl Med. 2020 Oct 2. pii: jnumed.120.250597. doi: 10.2967/jnumed.120.250597.
    PubMed     Abstract available

  268. CRANDALL JP, Fraum TJ, Lee M, Jiang L, et al
    Repeatability of (18)F-FDG PET Radiomic Features in Cervical Cancer.
    J Nucl Med. 2020 Oct 2. pii: jnumed.120.247999. doi: 10.2967/jnumed.120.247999.
    PubMed     Abstract available

  269. YAMADA S, Tsuyoshi H, Yamamoto M, Tsujikawa T, et al
    Prognostic value of 16alpha-[(18)F]-fluoro-17beta-estradiol positron emission tomography as a predictor of disease outcome in endometrial cancer: A prospective study.
    J Nucl Med. 2020 Oct 2. pii: jnumed.120.244319. doi: 10.2967/jnumed.120.244319.
    PubMed     Abstract available

  270. MARIANI G, Tonacchera M, Grosso M, Orsolini F, et al
    The role of nuclear medicine in the clinical management of benign thyroid disorders. Part 1. Hyperthyroidism.
    J Nucl Med. 2020 Oct 2. pii: jnumed.120.243170. doi: 10.2967/jnumed.120.243170.
    PubMed     Abstract available

  271. JACENE HA
    2020 SNMMI Highlights Lecture: General Nuclear Medicine and Molecular Imaging.
    J Nucl Med. 2020;61:17N-23N.

  272. BARTHEL H
    First Tau PET Tracer Approved: Toward Accurate In Vivo Diagnosis of Alzheimer Disease.
    J Nucl Med. 2020;61:1409-1410.

  273. SKALI H, Murthy VL, Paez D, Choi EM, et al
    Guidance and Best Practices for Reestablishment of Non-Emergent Care in Nuclear Cardiology Laboratories During the Coronavirus Disease 2019 (COVID-19) Pandemic: An Information Statement from ASNC, IAEA, and SNMMI.
    J Nucl Med. 2020;61:1534-1539.

  274. KOYCHEV I, Hofer M, Friedman N
    Correlation of Alzheimer Disease Neuropathologic Staging with Amyloid and Tau Scintigraphic Imaging Biomarkers.
    J Nucl Med. 2020;61:1413-1418.
    PubMed     Abstract available

  275. MATTAY VS, Fotenos AF, Ganley CJ, Marzella L, et al
    Brain Tau Imaging: Food and Drug Administration Approval of (18)F-Flortaucipir Injection.
    J Nucl Med. 2020;61:1411-1412.

  276. DARR C, Harke NN, Radtke JP, Yirga L, et al
    Intraoperative (68)Ga-PSMA Cerenkov Luminescence Imaging for Surgical Margins in Radical Prostatectomy: A Feasibility Study.
    J Nucl Med. 2020;61:1500-1506.
    PubMed     Abstract available

    September 2020
  277. ZUKOTYNSKI K, Gaudet V, Uribe CF, Mathotaarachchi S, et al
    Machine Learning in Nuclear Medicine: Part 2-Neural Networks and Clinical Aspects.
    J Nucl Med. 2020 Sep 25. pii: jnumed.119.231837. doi: 10.2967/jnumed.119.231837.
    PubMed     Abstract available

  278. BOYLE AJ, Tong J, Zoghbi S, Pike VW, et al
    Repurposing [(11)C]PS13 for PET imaging of cyclooxygenase-1 (COX-1) in ovarian cancer xenograft mouse models.
    J Nucl Med. 2020 Sep 25. pii: jnumed.120.249367. doi: 10.2967/jnumed.120.249367.
    PubMed     Abstract available

  279. BUCKNOR MD, Lichtensztajn DY, Lin TK, Borno HT, et al
    Disparities in PET imaging for prostate cancer at a tertiary academic medical center.
    J Nucl Med. 2020 Sep 25. pii: jnumed.120.251751. doi: 10.2967/jnumed.120.251751.
    PubMed     Abstract available

  280. FOSTER CC, Davis RA, Hausner SH, Sutcliffe JL, et al
    alphalphavbeta6 targeted molecular PET/CT imaging of lung post SARS-CoV-2 infection.
    J Nucl Med. 2020 Sep 18. pii: jnumed.120.255364. doi: 10.2967/jnumed.120.255364.
    PubMed     Abstract available

  281. DAS JP, Vargas HA, Ghafoor S, Goh AC, et al
    Clinical utility of (18)F-FDG PET/CT in staging and treatment planning of urachal adenocarcinoma.
    J Nucl Med. 2020 Sep 18. pii: jnumed.120.251561. doi: 10.2967/jnumed.120.251561.
    PubMed     Abstract available

  282. CHEN DL, Ballout S, Chen L, Cheriyan J, et al
    Consensus recommendations on the use of (18)F-FDG PET/CT in lung disease.
    J Nucl Med. 2020 Sep 18. pii: jnumed.120.244780. doi: 10.2967/jnumed.120.244780.
    PubMed     Abstract available

  283. FAROLFI A, Hirmas N, Gafita A, Weber M, et al
    PSMA-PET identifies PCWG3 target populations with superior accuracy and reproducibility when compared to conventional imaging: a multicenter retrospective study.
    J Nucl Med. 2020 Sep 11. pii: jnumed.120.246603. doi: 10.2967/jnumed.120.246603.
    PubMed     Abstract available

  284. STEPHENS DM, Li H, Schoder H, Friedberg J, et al
    Reply to: Interim PET assessment of advanced Hodgkin Lymphoma: is it sufficient?
    J Nucl Med. 2020 Sep 11. pii: jnumed.120.242685. doi: 10.2967/jnumed.120.242685.

  285. JUNG KH, Park JW, Lee JH, Lee EJ, et al
    (89)Zr Labeled Anti-PD-L1 Antibody PET Monitors Gemcitabine Therapy-Induced Modulation of Tumor PD-L1 Expression.
    J Nucl Med. 2020 Sep 11. pii: jnumed.120.250720. doi: 10.2967/jnumed.120.250720.
    PubMed     Abstract available

  286. VALKEMA MJ, van der Wilk BJ, Eyck BM, Wijnhoven BPL, et al
    Surveillance of clinically complete responders using serial (18)F-FDG PET/CT scans in patients with esophageal cancer after neoadjuvant chemoradiotherapy.
    J Nucl Med. 2020 Sep 4. pii: jnumed.120.247981. doi: 10.2967/jnumed.120.247981.
    PubMed     Abstract available

  287. HUANG Y, Zhao N, Wang YH, Truillet C, et al
    The synthesis and structural requirements for measuring glucocorticoid receptor expression in vivo with (+/-)-(11)C-YJH08 PET.
    J Nucl Med. 2020 Sep 4. pii: jnumed.120.249755. doi: 10.2967/jnumed.120.249755.
    PubMed     Abstract available

  288. GALLDIKS N, Abdulla DS, Scheffler M, Wolpert F, et al
    Treatment Monitoring of Immunotherapy and Targeted Therapy using (18)F-FET PET in Patients with Melanoma and Lung Cancer Brain Metastases: Initial Experiences.
    J Nucl Med. 2020 Sep 4. pii: jnumed.120.248278. doi: 10.2967/jnumed.120.248278.
    PubMed     Abstract available

  289. DORBALA S, Park MA, Cuddy S, Singh V, et al
    Absolute Quantitation of Cardiac (99m)Tc-pyrophophate Using Cadmium Zinc Telluride-based SPECT/CT.
    J Nucl Med. 2020 Sep 4. pii: jnumed.120.247312. doi: 10.2967/jnumed.120.247312.
    PubMed     Abstract available

  290. IRAVANI A, Hicks RJ
    Imaging the cancer immune environment and its response to pharmacological intervention- Part 2- The Role of Novel PET Agents.
    J Nucl Med. 2020 Sep 4. pii: jnumed.120.248823. doi: 10.2967/jnumed.120.248823.
    PubMed     Abstract available

  291. LI YR, Roach M 3rd
    The Roach Equation: Value of Old Clinical Tools in the Era of New Molecular Imaging.
    J Nucl Med. 2020;61:1292-1293.

  292. CASTELLO A, Lopci E
    Reply: Diagnosis of Hyperprogressive Disease in Patients Treated with Checkpoint Inhibitors Using (18)F-FDG PET/CT.
    J Nucl Med. 2020;61:1405.

  293. OSBORNE JR, Hope TA
    A Conversation Between Joseph Osborne and Thomas Hope.
    J Nucl Med. 2020;61:1275-1277.

  294. HENRY KE, Chaney AM, Nagle VL, Cropper HC, et al
    Demarcation of Sepsis-Induced Peripheral and Central Acidosis with pH (Low) Insertion Cycle Peptide.
    J Nucl Med. 2020;61:1361-1368.
    PubMed     Abstract available

    August 2020
  295. POLI GL, Coca MA, Torres LA, Fahey FH, et al
    Developing and implementing an imaging optimization study in pediatric nuclear medicine: Experience and recommendations from an IAEA Coordinated Research Project.
    J Nucl Med. 2020 Aug 28. pii: jnumed.120.244616. doi: 10.2967/jnumed.120.244616.
    PubMed     Abstract available

  296. NAGANAWA M, Nabulsi NB, Henry S, Matuskey D, et al
    First in Human Assessment of the Novel M1 Muscarinic Acetylcholine Receptor PET Radiotracer (11)C-LSN3172176.
    J Nucl Med. 2020 Aug 28. pii: jnumed.120.246967. doi: 10.2967/jnumed.120.246967.
    PubMed     Abstract available

  297. RYDEN T, van Essen M, Marin I, Svensson J, et al
    Deep learning generation of synthetic intermediate projections improves (177)Lu SPECT images reconstructed with sparsely acquired projections.
    J Nucl Med. 2020 Aug 28. pii: jnumed.120.245548. doi: 10.2967/jnumed.120.245548.
    PubMed     Abstract available

  298. KESSLER L, Schlitter AM, Kroenke M, von Werder A, et al
    First experience using F-18-flubrobenguane PET imaging in patients with the suspicion of pheochromocytoma or paraganglioma.
    J Nucl Med. 2020 Aug 28. pii: jnumed.120.248021. doi: 10.2967/jnumed.120.248021.
    PubMed     Abstract available

  299. SANCHEZ-CATASUS CA, Bohnen NI, Yeh FC, D'Cruz N, et al
    Dopaminergic nigrostriatal connectivity in early Parkinson disease: in vivo neuroimaging study of (11)C-DTBZ PET combined with correlational tractography.
    J Nucl Med. 2020 Aug 28. pii: jnumed.120.248500. doi: 10.2967/jnumed.120.248500.
    PubMed     Abstract available

  300. WERNER RA, Derlin T, Rowe SP, Bundschuh L, et al
    High Interobserver Agreement for the Standardized Reporting System SSTR-RADS 1.0 on Somatostatin Receptor PET/CT.
    J Nucl Med. 2020 Aug 28. pii: jnumed.120.245464. doi: 10.2967/jnumed.120.245464.
    PubMed     Abstract available

  301. NAGANAWA M, Li S, Nabulsi NB, Henry S, et al
    First-in-human evaluation of (18)F-SynVesT-1, a novel radioligand for PET imaging of synaptic vesicle protein 2A.
    J Nucl Med. 2020 Aug 28. pii: jnumed.120.249144. doi: 10.2967/jnumed.120.249144.
    PubMed     Abstract available

  302. FILSS CP, Stegmayr C, Lohmann P, Galldiks N, et al
    Reply to: Flare phenomenon in O-(2-[(18)F]-Fluoroethyl)-L-Tyrosine PET after resection of gliomas: potential contribution from postoperative ischemia.
    J Nucl Med. 2020 Aug 28. pii: jnumed.120.251819. doi: 10.2967/jnumed.120.251819.

  303. MACASKILL MG, Stadulyte A, Williams L, Morgan TEF, et al
    Quantification of macrophage-driven inflammation during myocardial infarction with (18)F-LW223, a novel TSPO radiotracer with binding independent of the rs6971 human polymorphism.
    J Nucl Med. 2020 Aug 28. pii: jnumed.120.243600. doi: 10.2967/jnumed.120.243600.
    PubMed     Abstract available

  304. KUMAR M, Salem K, Jeffery JJ, Yan Y, et al
    Longitudinal molecular imaging of progesterone receptor reveals early differential response to endocrine therapy in breast cancer with an activating ESR1 mutation.
    J Nucl Med. 2020 Aug 28. pii: jnumed.120.249508. doi: 10.2967/jnumed.120.249508.
    PubMed     Abstract available

  305. NICOLAY NH, Ruhle A, Wiedenmann N, Niedermann G, et al
    Lymphocyte Infiltration Determines the Hypoxia-Dependent Response to Definitive Chemoradiation in Head-and-Neck Cancer - Results from a Prospective Imaging Trial.
    J Nucl Med. 2020 Aug 28. pii: jnumed.120.248633. doi: 10.2967/jnumed.120.248633.
    PubMed     Abstract available

  306. SIITONEN R, Moisio OA, Lankinen P, Li XG, et al
    First-in-Human Study of (68)Ga-DOTA-Siglec-9, PET Ligand Targeting Vascular Adhesion Protein 1.
    J Nucl Med. 2020 Aug 17. pii: jnumed.120.250696. doi: 10.2967/jnumed.120.250696.
    PubMed     Abstract available

  307. SPRUTE K, Kramer V, Koerber S, Meneses M, et al
    Diagnostic accuracy of (18)F-PSMA-1007-PET/CT imaging for lymph node staging of prostate carcinoma in primary and biochemical recurrence.
    J Nucl Med. 2020 Aug 17. pii: jnumed.120.246363. doi: 10.2967/jnumed.120.246363.
    PubMed     Abstract available

  308. VAN ES SC, Velleman T, Elias SG, Bensch F, et al
    Assessment of Bone Lesions with (18)F-FDG-PET Compared to (99m)Technetium Bone Scintigraphy Leads to Clinically Relevant Differences in Metastatic Breast Cancer Management.
    J Nucl Med. 2020 Aug 17. pii: jnumed.120.244640. doi: 10.2967/jnumed.120.244640.
    PubMed     Abstract available

  309. BRAGINA O, von Witting E, Garousi J, Zelchan R, et al
    Phase I study of (99m)Tc-ADAPT6, a scaffold protein-based probe for visualization of HER2 expression in breast cancer.
    J Nucl Med. 2020 Aug 17. pii: jnumed.120.248799. doi: 10.2967/jnumed.120.248799.
    PubMed     Abstract available

  310. KOHLI P, Kelly VJ, Hibbert K, Corleis B, et al
    PET Imaging Reveals Early Pulmonary Perfusion Abnormalities in HIV Infection Similar to Smoking.
    J Nucl Med. 2020 Aug 6. pii: jnumed.120.245977. doi: 10.2967/jnumed.120.245977.
    PubMed     Abstract available

  311. REGINE K, Wittig T, Georgi TW, Kurch L, et al
    Comparison of interim PET response to second-line vs. to first-line treatment in classical Hodgkin lymphoma - contribution to the development of response criteria for relapsed or progressive disease.
    J Nucl Med. 2020 Aug 6. pii: jnumed.120.247924. doi: 10.2967/jnumed.120.247924.
    PubMed     Abstract available

  312. FOSBOL MO, Kurbegovic S, Johannesen HH, Roder MA, et al
    Urokinase Plasminogen Activator Receptor (uPAR) PET/MRI of Prostate Cancer for Non-invasive Evaluation of Aggressiveness: a Prospective Phase II Clinical Trial Comparing with Gleason Score.
    J Nucl Med. 2020 Aug 6. pii: jnumed.120.248120. doi: 10.2967/jnumed.120.248120.
    PubMed     Abstract available

  313. SCHINDLER TH, Bateman TM, Berman DS, Chareonthaitawee P, et al
    Appropriate Use Criteria for PET Myocardial Perfusion Imaging.
    J Nucl Med. 2020;61:1221-1265.

  314. CZERNIN J
    The Future of Nuclear Medicine Depends on the Quality of Its Research: Researchers at the University of Heidelberg Receive the Award for Best Article of the Year.
    J Nucl Med. 2020;61:1087.

  315. BODEI L, Bergsland E, de Herder WW, Ferone D, et al
    Peptide Receptor Radionuclide Therapy During the COVID-19 Pandemic: Are There Any Concerns?
    J Nucl Med. 2020;61:1094-1095.

  316. MARTIN KC, Czernin J
    A Conversation Between Kelsey Martin and Johannes Czernin.
    J Nucl Med. 2020;61:1091-1093.

  317. ZINDEL C, Herrmann K
    A Conversation Between Christoph Zindel and Ken Herrmann.
    J Nucl Med. 2020;61:1088-1090.

  318. MUELLER JJ, Dauer LT, Murali R, Iasonos A, et al
    Positron Lymphography via Intracervical (18)F-FDG Injection for Presurgical Lymphatic Mapping in Cervical and Endometrial Malignancies.
    J Nucl Med. 2020;61:1123-1130.
    PubMed     Abstract available

  319. TRAN-GIA J, Salas-Ramirez M, Lassmann M
    What You See Is Not What You Get: On the Accuracy of Voxel-Based Dosimetry in Molecular Radiotherapy.
    J Nucl Med. 2020;61:1178-1186.
    PubMed     Abstract available

  320. CISTARO A, Quartuccio N, Piccardo A, Fania P, et al
    (18)F-FDG PET Identifies Altered Brain Metabolism in Patients with Cri du Chat Syndrome.
    J Nucl Med. 2020;61:1195-1199.
    PubMed     Abstract available

  321. POLLARD JH, Raman C, Zakharia Y, Tracy CR, et al
    Quantitative Test-Retest Measurement of (68)Ga-PSMA-HBED-CC in Tumor and Normal Tissue.
    J Nucl Med. 2020;61:1145-1152.
    PubMed     Abstract available

    July 2020
  322. CHODYLA M, Demircioglu A, Schaarschmidt BM, Bertram S, et al
    Evaluation of (18)F-FDG PET and DWI datasets for the prediction of therapy response of soft tissues sarcomas under neoadjuvant isolated limb perfusion.
    J Nucl Med. 2020 Jul 31. pii: jnumed.120.248260. doi: 10.2967/jnumed.120.248260.
    PubMed     Abstract available

  323. THERRIAULT J, Benedet A, Pascoal TA, Savard M, et al
    Determining Amyloid-beta positivity using [(18)F]AZD4694 PET imaging.
    J Nucl Med. 2020 Jul 31. pii: jnumed.120.245209. doi: 10.2967/jnumed.120.245209.
    PubMed     Abstract available

  324. GRIMALDI S, Lagarde S, Harle JR, Boucraut J, et al
    Autoimmune encephalitis concomitant with SARS-CoV-2 infection: insight from (18)F-FDG PET imaging and neuronal autoantibodies.
    J Nucl Med. 2020 Jul 24. pii: jnumed.120.249292. doi: 10.2967/jnumed.120.249292.
    PubMed     Abstract available

  325. FREUDENBERG LS, Paez D, Giammarile F, Cerci JJ, et al
    Global Impact of COVID-19 on Nuclear Medicine Departments: An International Survey in April 2020.
    J Nucl Med. 2020 Jul 24. pii: jnumed.120.249821. doi: 10.2967/jnumed.120.249821.
    PubMed     Abstract available

  326. LAURELL GL, Plaven-Sigray P, Jucaite A, Varrone A, et al
    Non-displaceable binding is a potential confounding factor in (11)CPBR28 TSPO PET studies.
    J Nucl Med. 2020 Jul 17. pii: jnumed.120.243717. doi: 10.2967/jnumed.120.243717.
    PubMed     Abstract available

  327. KULTERER OC, Pfaff S, Wadsak W, Garstka N, et al
    A microdosing study with (99m)Tc-PHC-102 for the SPECT/CT imaging of primary and metastatic lesions in renal cell carcinoma patients.
    J Nucl Med. 2020 Jul 17. pii: jnumed.120.245530. doi: 10.2967/jnumed.120.245530.
    PubMed     Abstract available

  328. ULANER GA, Jhaveri K, Chardarlapaty S, Hatzoglou V, et al
    Head-to-head evaluation of (18)F-FES and (18)F-FDG PET/CT in metastatic invasive lobular breast cancer.
    J Nucl Med. 2020 Jul 17. pii: jnumed.120.247882. doi: 10.2967/jnumed.120.247882.
    PubMed     Abstract available

  329. NABAVIZADEH SA, Nasrallah IM, Pryma DA
    Flare phenomenon in O-(2-[(18)F]-Fluoroethyl)-L-Tyrosine PET after resection of gliomas: potential contribution from postoperative ischemia.
    J Nucl Med. 2020 Jul 9. pii: jnumed.120.251116. doi: 10.2967/jnumed.120.251116.

  330. CUTLER CS, Bailey EA, Kumar V, Schwarz SW, et al
    Global Issues of Radiopharmaceutical Access and Availability: a Nuclear Medicine Global Initiative Project.
    J Nucl Med. 2020 Jul 9. pii: jnumed.120.247197. doi: 10.2967/jnumed.120.247197.
    PubMed     Abstract available

  331. HARADA R, Hayakawa Y, Ezura M, Lerdsirisuk P, et al
    (18)F-SMBT-1: A Selective and Reversible Positron-Emission Tomography Tracer for Monoamine Oxidase-B Imaging.
    J Nucl Med. 2020 Jul 9. pii: jnumed.120.244400. doi: 10.2967/jnumed.120.244400.
    PubMed     Abstract available

  332. TATEKAWA H, Hagiwara A, Yao J, Oughourlian TC, et al
    Voxel-Wise and Patient-Wise Correlation of (18)F-FDOPA PET, rCBV, and ADC in Treatment-Naive Diffuse Gliomas with Different Molecular Subtypes.
    J Nucl Med. 2020 Jul 9. pii: jnumed.120.247411. doi: 10.2967/jnumed.120.247411.
    PubMed     Abstract available

  333. NAGANAWA M, Gallezot JD, Finnema S, Matuskey D, et al
    Simplified Quantification of (11)C-UCB-J PET Evaluated in a Large Human Cohort.
    J Nucl Med. 2020 Jul 9. pii: jnumed.120.243949. doi: 10.2967/jnumed.120.243949.
    PubMed     Abstract available

  334. RUSSELL J, Grkovski M, O'Donoghue IJ, Kalidindi TM, et al
    Predicting gemcitabine delivery by (18)F-FAC PET in murine models of pancreatic cancer.
    J Nucl Med. 2020 Jul 9. pii: jnumed.120.246926. doi: 10.2967/jnumed.120.246926.
    PubMed     Abstract available

  335. SPANGLER-BICKELL MG, Deller TW, Bettinardi V, Jansen F, et al
    Ultra-Fast List-Mode Reconstruction of Short PET Frames and Example Applications.
    J Nucl Med. 2020 Jul 9. pii: jnumed.120.245597. doi: 10.2967/jnumed.120.245597.
    PubMed     Abstract available

  336. JAIN P, Chaney A, Carlson ML, Jackson IM, et al
    Neuroinflammation PET imaging: Current opinion and future directions.
    J Nucl Med. 2020 Jul 3. pii: jnumed.119.229443. doi: 10.2967/jnumed.119.229443.
    PubMed     Abstract available

  337. HAMMES J, Bischof GN, Bohn KP, Onur O, et al
    One stop shop: Flortaucipir PET differentiates amyloid positive and negative forms of neurodegenerative diseases.
    J Nucl Med. 2020 Jul 3. pii: jnumed.120.244061. doi: 10.2967/jnumed.120.244061.
    PubMed     Abstract available

  338. BINI J, Carson RE, Cline GW
    Reply to LTE: (11)C-(+)-PHNO Trapping Reversibility for Quantitative PET Imaging of Beta-Cell-Mass in Patients with Type-1 Diabetes.
    J Nucl Med. 2020 Jul 3. pii: jnumed.120.250985. doi: 10.2967/jnumed.120.250985.

  339. VAN DEN WYNGAERT T, Elvas F, De Schepper S, Kennedy JA, et al
    SPECT/CT - standing on the shoulders of giants, it is time to reach for the sky!
    J Nucl Med. 2020 Jul 3. pii: jnumed.119.236943. doi: 10.2967/jnumed.119.236943.
    PubMed     Abstract available

  340. ZUBAL IG
    Time for a Next-Generation Nuclear Medicine Gamma Camera?
    J Nucl Med. 2020;61:16N.

  341. MURTHY VL, Bateman TM, Chen W, Malhotra S, et al
    Impact of the ISCHEMIA Trial on Stress Nuclear Myocardial Perfusion Imaging.
    J Nucl Med. 2020;61:962-964.

  342. BODINI B, Poirion E, Tonietto M, Benoit C, et al
    Individual Mapping of Innate Immune Cell Activation Is a Candidate Marker of Patient-Specific Trajectories of Worsening Disability in Multiple Sclerosis.
    J Nucl Med. 2020;61:1043-1049.
    PubMed     Abstract available

  343. KLINGLER S, Fay R, Holland JP
    Light-Induced Radiosynthesis of (89)Zr-DFO-Azepin-Onartuzumab for Imaging the Hepatocyte Growth Factor Receptor.
    J Nucl Med. 2020;61:1072-1078.
    PubMed     Abstract available

  344. KNIGHT JC, Torres JB, Goldin R, Mosley M, et al
    Early Detection in a Mouse Model of Pancreatic Cancer by Imaging DNA Damage Response Signaling.
    J Nucl Med. 2020;61:1006-1013.
    PubMed     Abstract available

  345. QUELVEN I, Monteil J, Sage M, Saidi A, et al
    (212)Pb alpha-Radioimmunotherapy Targeting CD38 in Multiple Myeloma: A Preclinical Study.
    J Nucl Med. 2020;61:1058-1065.
    PubMed     Abstract available

  346. YU Q, Huang S, Wu Z, Zheng J, et al
    Label-Free Visualization of Early Cancer Hepatic Micrometastasis and Intraoperative Image-Guided Surgery by Photoacoustic Imaging.
    J Nucl Med. 2020;61:1079-1085.
    PubMed     Abstract available

    June 2020
  347. GIESEL F, Adeberg S, Syed M, Lindner T, et al
    FAPI-74 PET/CT Using Either (18)F-AlF or Cold-kit (68)Ga-labeling: Biodistribution, Radiation Dosimetry and Tumor Delineation in Lung Cancer Patients.
    J Nucl Med. 2020 Jun 26. pii: jnumed.120.245084. doi: 10.2967/jnumed.120.245084.
    PubMed     Abstract available

  348. PETERSON LM, Kurland BF, Yan F, Novakova-Jiresova A, et al
    (18)F-Fluoroestradiol ((18)F-FES)-PET imaging in a Phase II trial of vorinostat to restore endocrine sensitivity in ER+/HER2- metastatic breast cancer.
    J Nucl Med. 2020 Jun 26. pii: jnumed.120.244459. doi: 10.2967/jnumed.120.244459.
    PubMed     Abstract available

  349. VAN ROEKEL C, Bastiaannet R, Smits MLJ, Bruijnen RC, et al
    Dose-effect relationships of holmium-166 radioembolization in colorectal cancer.
    J Nucl Med. 2020 Jun 26. pii: jnumed.120.243832. doi: 10.2967/jnumed.120.243832.
    PubMed     Abstract available

  350. NOTO RB
    Diversity, not Divisiveness, is the Future of Nuclear Medicine.
    J Nucl Med. 2020 Jun 23. pii: jnumed.120.250035. doi: 10.2967/jnumed.120.250035.

  351. CZERNIN J
    Reply to: Diversity, not Divisiveness, is the Future of Nuclear Medicine.
    J Nucl Med. 2020 Jun 23. pii: jnumed.120.250415. doi: 10.2967/jnumed.120.250415.

  352. SHAFFER T, Gambhir SS, Aalipour A, Schurch C, et al
    PET imaging of the natural killer cell activation receptor NKp30.
    J Nucl Med. 2020 Jun 12. pii: jnumed.119.233163. doi: 10.2967/jnumed.119.233163.
    PubMed     Abstract available

  353. FERDINANDUS J, Barbato F, Chodyla M, Fendler WP, et al
    Volumetric PET response assessment outperforms conventional criteria in patients receiving high-dose pembrolizumab for malignant mesothelioma.
    J Nucl Med. 2020 Jun 12. pii: jnumed.120.245803. doi: 10.2967/jnumed.120.245803.
    PubMed     Abstract available

  354. SHARMA R, Inglese M, Dubash S, Lu H, et al
    Monitoring response to transarterial chemoembolization in hepatocellular carcinoma using (18)F-Fluorothymidine Positron Emission Tomography.
    J Nucl Med. 2020 Jun 8. pii: jnumed.119.240598. doi: 10.2967/jnumed.119.240598.
    PubMed     Abstract available

  355. LUO Y, Pan Q, Yang H, Peng L, et al
    Fibroblast activation protein targeted PET/CT with (68)Ga-FAPI for imaging IgG4-related disease: comparison to (18)F-FDG PET/CT.
    J Nucl Med. 2020 Jun 8. pii: jnumed.120.244723. doi: 10.2967/jnumed.120.244723.
    PubMed     Abstract available

  356. KESNER AL
    Data-driven motion correction in clinical PET - a joint accomplishment of creative academia and industry.
    J Nucl Med. 2020 Jun 8. pii: jnumed.120.248187. doi: 10.2967/jnumed.120.248187.

  357. SCHMALL JP, Surti S, Otero H, Servaes S, et al
    Investigating low-dose image quality in whole-body pediatric (18)F-FDG scans using TOF-PET/MRI.
    J Nucl Med. 2020 Jun 1. pii: jnumed.119.240127. doi: 10.2967/jnumed.119.240127.
    PubMed     Abstract available

  358. Guidance and best practices for nuclear cardiology laboratories during the coronavirus disease 2019 (COVID-19) pandemic: An Information Statement from ASNC and SNMMI.
    J Nucl Med. 2020;61:784-791.

  359. COOK GJR, Goh V
    Molecular Imaging of Bone Metastases and Their Response to Therapy.
    J Nucl Med. 2020;61:799-806.
    PubMed     Abstract available

    May 2020
  360. PRATT EC, Isaac E, Stater E, Yang G, et al
    Synthesis of novel PET tracer (124)I-trametinib for MAPK/ERK kinase distribution and resistance monitoring.
    J Nucl Med. 2020 May 22. pii: jnumed.120.241901. doi: 10.2967/jnumed.120.241901.
    PubMed     Abstract available

  361. WEBER M, Kurek CE, Barbato F, Eiber M, et al
    PSMA-ligand PET for early castration-resistant prostate cancer: a retrospective single-center study.
    J Nucl Med. 2020 May 22. pii: jnumed.120.245456. doi: 10.2967/jnumed.120.245456.
    PubMed     Abstract available

  362. IRAVANI A, Hicks RJ
    Imaging the cancer immune environment and its response to pharmacological intervention- Part 1- The role of FDG PET/CT.
    J Nucl Med. 2020 May 22. pii: jnumed.119.234278. doi: 10.2967/jnumed.119.234278.
    PubMed     Abstract available

  363. KLINGENBERG S, Jochumsen MR, Ulhoi BP, Fredsoe J, et al
    (68)Ga-PSMA PET/CT for primary NM staging of high-risk prostate cancer.
    J Nucl Med. 2020 May 22. pii: jnumed.120.245605. doi: 10.2967/jnumed.120.245605.
    PubMed     Abstract available

  364. HEO GS, Bajpai G, Li W, Luehmann HP, et al
    Targeted PET Imaging of Chemokine Receptor 2+ Monocytes and Macrophages in the Injured Heart.
    J Nucl Med. 2020 May 22. pii: jnumed.120.244673. doi: 10.2967/jnumed.120.244673.
    PubMed     Abstract available

  365. LOFT M, Carlsen EA, Johnbeck CB, Johannesen HH, et al
    (64)Cu-DOTATATE PET in Patients with Neuroendocrine Neoplasms: Prospective, Head-to-Head Comparison of Imaging at 1 Hour and 3 Hours Post-Injection.
    J Nucl Med. 2020 May 22. pii: jnumed.120.244509. doi: 10.2967/jnumed.120.244509.
    PubMed     Abstract available

  366. DITTMANN H, Kaltenbach S, Weissinger M, Fiz F, et al
    The prognostic value of quantitative bone scan SPECT/CT prior to (223)Ra treatment in metastatic castration-resistant prostate cancer (mCRPC).
    J Nucl Med. 2020 May 22. pii: jnumed.119.240408. doi: 10.2967/jnumed.119.240408.
    PubMed     Abstract available

  367. BAGUNA TORRES J, Mosley M, Koustoulidou S, Hopkins S, et al
    Radiolabeled cCPE Peptides for SPECT Imaging of Claudin-4 Overexpression in Pancreatic Cancer.
    J Nucl Med. 2020 May 15. pii: jnumed.120.243113. doi: 10.2967/jnumed.120.243113.
    PubMed     Abstract available

  368. ABOIAN M, Huang SY, Pampaloni MH, Hawkins RA, et al
    (124)I-MIBG PET-CT to monitor metastatic disease in children with relapsed neuroblastoma.
    J Nucl Med. 2020 May 15. pii: jnumed.120.243139. doi: 10.2967/jnumed.120.243139.
    PubMed     Abstract available

  369. BARTHEL H, Seibyl J, Lammertsma AA, Villemagne VL, et al
    Exploiting the Full Potential of Beta-Amyloid and Tau PET Imaging for Drug Efficacy Testing.
    J Nucl Med. 2020 May 15. pii: jnumed.119.228346. doi: 10.2967/jnumed.119.228346.

  370. SHI Z, Fu LP, Zhang N, Zhao X, et al
    Amyloid PET in Dementia Syndromes: A Chinese Multicenter Study.
    J Nucl Med. 2020 May 8. pii: jnumed.119.240325. doi: 10.2967/jnumed.119.240325.
    PubMed     Abstract available

  371. REKOWSKI J, Huttmann A, Schmitz C, Muller SP, et al
    Interim PET evaluation in diffuse large B-cell lymphoma employing published recommendations: Comparison of the Deauville 5-point scale and the DeltaSUVmax method.
    J Nucl Med. 2020 May 8. pii: jnumed.120.244145. doi: 10.2967/jnumed.120.244145.
    PubMed     Abstract available

  372. ZUBAL IG
    Time for a Next-Generation Nuclear Medicine Gamma Camera? [NEWSLINE].
    J Nucl Med. 2020 May 8. pii: jnumed.120.249219. doi: 10.2967/jnumed.120.249219.

  373. HARSINI S, Saprunoff H, Alden TM, Mohammadi B, et al
    The effects of monosodium glutamate on PSMA radiotracer uptake in men with recurrent prostate cancer: a prospective, randomized, double-blind, placebo-controlled intra-individual imaging study.
    J Nucl Med. 2020 May 8. pii: jnumed.120.246983. doi: 10.2967/jnumed.120.246983.
    PubMed     Abstract available

  374. GORDON L
    ABNM: Helping Diplomates and Trainees During the COVID-19 Pandemic.
    J Nucl Med. 2020;61:13N.

  375. CZERNIN J
    The Standard of Care: From Nuclear Radiology to Nuclear Medicine.
    J Nucl Med. 2020;61:637.

  376. FENDLER WP, Ferdinandus J, Czernin J, Eiber M, et al
    Impact of (68)Ga-PSMA-11 PET on the Management of recurrent Prostate Cancer in a Prospective Single-Arm Clinical Trial.
    J Nucl Med. 2020 May 1. pii: jnumed.120.242180. doi: 10.2967/jnumed.120.242180.
    PubMed     Abstract available

  377. STUTVOET TS, van der Veen EL, Kol A, Antunes IF, et al
    Molecular imaging of PD-L1 expression and dynamics with the adnectin-based PET tracer (18)F-BMS-986192.
    J Nucl Med. 2020 May 1. pii: jnumed.119.241364. doi: 10.2967/jnumed.119.241364.
    PubMed     Abstract available

  378. RIPP I, Stadhouders T, Savio A, Goldhardt O, et al
    Integrity of neurocognitive networks in dementing disorders as measured with simultaneous PET/fMRI.
    J Nucl Med. 2020 May 1. pii: jnumed.119.234930. doi: 10.2967/jnumed.119.234930.
    PubMed     Abstract available

  379. LOPEZ MORA DA, Flotats A, Fuentes-Ocampo F, Carrio I, et al
    Reported differences between Digital and Analog PET/CT studies.
    J Nucl Med. 2020 May 1. pii: jnumed.120.244608. doi: 10.2967/jnumed.120.244608.

  380. RULLMANN M, McLeod A, Grothe M, Sabri O, et al
    Reshaping the amyloid buildup curve in Alzheimer's disease? - Partial volume effect correction of longitudinal amyloid PET data.
    J Nucl Med. 2020 May 1. pii: jnumed.119.238477. doi: 10.2967/jnumed.119.238477.
    PubMed     Abstract available

  381. CUDA TJ, Riddell AD, Liu C, Whitehall VL, et al
    PET imaging quantifying (68)Ga-PSMA-11 uptake in metastatic colorectal cancer.
    J Nucl Med. 2020 May 1. pii: jnumed.119.233312. doi: 10.2967/jnumed.119.233312.
    PubMed     Abstract available

  382. CZERNIN J, Fanti S, Meyer PT, Allen-Auerbach M, et al
    Nuclear Medicine Operations in the Times of COVID-19: Strategies, Precautions, and Experiences.
    J Nucl Med. 2020;61:626-629.

  383. CARRIO I, Herrmann K
    A Conversation Between Ignasi Carrio and Ken Herrmann.
    J Nucl Med. 2020;61:638-640.

  384. O'NEILL E, Kersemans V, Allen PD, Terry SYA, et al
    Imaging DNA Damage Repair In Vivo After (177)Lu-DOTATATE Therapy.
    J Nucl Med. 2020;61:743-750.
    PubMed     Abstract available

  385. KRATOCHWIL C, Giesel FL, Heussel CP, Kazdal D, et al
    Patients Resistant Against PSMA-Targeting alpha-Radiation Therapy Often Harbor Mutations in DNA Damage-Repair-Associated Genes.
    J Nucl Med. 2020;61:683-688.
    PubMed     Abstract available

  386. ABBOTT EM, Falzone N, Lee BQ, Kartsonaki C, et al
    The Impact of Radiobiologically-Informed Dose Prescription on the Clinical Benefit of Yttrium-90 SIRT in Colorectal Cancer Patients.
    J Nucl Med. 2020 May 1. pii: jnumed.119.233650. doi: 10.2967/jnumed.119.233650.
    PubMed     Abstract available

    April 2020
  387. SEIFERT R, Herrmann K, Kleesiek J, Schafers MA, et al
    Semi-automatically quantified tumor volume using Ga-68-PSMA-11-PET as biomarker for survival in patients with advanced prostate cancer.
    J Nucl Med. 2020 Apr 24. pii: jnumed.120.242057. doi: 10.2967/jnumed.120.242057.
    PubMed     Abstract available

  388. HERHAUS P, Lipkova J, Lammer F, Yakushev I, et al
    CXCR4-targeted positron emission tomography imaging of central nervous system B-cell lymphoma.
    J Nucl Med. 2020 Apr 24. pii: jnumed.120.241703. doi: 10.2967/jnumed.120.241703.
    PubMed     Abstract available

  389. CHIU LW, Lawhn-Heath C, Behr S, Juarez R, et al
    Factors predicting metastatic disease in (68)Ga-PSMA-11 PET positive osseous lesions in prostate cancer.
    J Nucl Med. 2020 Apr 17. pii: jnumed.119.241174. doi: 10.2967/jnumed.119.241174.
    PubMed     Abstract available

  390. JUENGLING FD, Maldonado A, Wuest F, Schindler TH, et al
    The role of Nuclear Medicine for COVID-19 - Time to act now.
    J Nucl Med. 2020 Apr 17. pii: jnumed.120.246611. doi: 10.2967/jnumed.120.246611.

  391. WERNER RA, Thackeray JT, Diekmann J, Weiberg D, et al
    The Changing Face of Nuclear Cardiology: Guiding Cardiovascular Care towards Molecular Medicine.
    J Nucl Med. 2020 Apr 17. pii: jnumed.119.240440. doi: 10.2967/jnumed.119.240440.
    PubMed     Abstract available

  392. REYNOLDS JC, Maass-Moreno R, Thomas A, Ling A, et al
    FDG-PET assessment of malignant pleural mesothelioma: Total Lesion volume and Total Lesion Glycolysis; the central role of volume.
    J Nucl Med. 2020 Apr 13. pii: jnumed.119.238733. doi: 10.2967/jnumed.119.238733.
    PubMed     Abstract available

  393. JAHANDIDEH A, Uotila S, Stahle M, Virta J, et al
    Folate Receptor beta Targeted PET Imaging of Macrophages in Autoimmune Myocarditis.
    J Nucl Med. 2020 Apr 13. pii: jnumed.119.241356. doi: 10.2967/jnumed.119.241356.
    PubMed     Abstract available

  394. WEIDNER LD, Wakabayashi Y, Stolz LA, Collins MT, et al
    PET imaging of phosphodiesterase-4 identifies affected dysplastic bone in McCune-Albright syndrome, a genetic mosaic disorder.
    J Nucl Med. 2020 Apr 13. pii: jnumed.120.241976. doi: 10.2967/jnumed.120.241976.
    PubMed     Abstract available

  395. WALKER MD, Morgan AJ, Bradley KM, McGowan DR, et al
    Data Driven Respiratory Gating Outperforms Device-Based Gating for Clinical FDG PET/CT.
    J Nucl Med. 2020 Apr 3. pii: jnumed.120.242248. doi: 10.2967/jnumed.120.242248.
    PubMed     Abstract available

  396. HOFMAN MS
    ProPSMA: a callout to the nuclear medicine community to change practice with prospective, high-quality data.
    J Nucl Med. 2020 Apr 3. pii: jnumed.120.245647. doi: 10.2967/jnumed.120.245647.

  397. ALBANO D, Bertagna F, Bertolia M, Bosio G, et al
    J Nucl Med. 2020 Apr 1. pii: jnumed.120.246256. doi: 10.2967/jnumed.120.246256.
    PubMed     Abstract available

  398. ZUCKIER LS, Moadel RM, Haramati LB, Freeman L, et al
    Diagnostic evaluation of pulmonary embolism during the COVID-19 pandemic.
    J Nucl Med. 2020 Apr 1. pii: jnumed.120.245571. doi: 10.2967/jnumed.120.245571.

  399. SABOUR S
    Myocardial Blood Flow and Myocardial Flow Reserve After Cardiac Transplantation: Mistakes in Diagnostic Value and Prognosis.
    J Nucl Med. 2020;61:622.

  400. SUNDERLAND JJ, Czernin J, Hope T
    A Conversation with John Sunderland, Johannes Czernin, and Thomas Hope.
    J Nucl Med. 2020;61:477-479.

  401. MAYERHOEFER ME, Materka A, Langs G, Haggstrom I, et al
    Introduction to Radiomics.
    J Nucl Med. 2020;61:488-495.
    PubMed     Abstract available

    The Academic NDA: Justification, Process, and Lessons Learned.
    J Nucl Med. 2020;61:480-487.
    PubMed     Abstract available

  403. GLASENAPP A, Derlin K, Wang Y, Bankstahl M, et al
    Multimodality Imaging of Inflammation and Ventricular Remodeling in Pressure-Overload Heart Failure.
    J Nucl Med. 2020;61:590-596.
    PubMed     Abstract available

  404. BASTIAANNET R, van Roekel C, Smits MLJ, Elias SG, et al
    First Evidence for a Dose-Response Relationship in Patients Treated with (166)Ho Radioembolization: A Prospective Study.
    J Nucl Med. 2020;61:608-612.
    PubMed     Abstract available

  405. PANDIT-TASKAR N, Postow MA, Hellmann MD, Harding JJ, et al
    First-in-Humans Imaging with (89)Zr-Df-IAB22M2C Anti-CD8 Minibody in Patients with Solid Malignancies: Preliminary Pharmacokinetics, Biodistribution, and Lesion Targeting.
    J Nucl Med. 2020;61:512-519.
    PubMed     Abstract available

  406. WATABE T, Liu Y, Kaneda-Nakashima K, Shirakami Y, et al
    Theranostics Targeting Fibroblast Activation Protein in the Tumor Stroma: (64)Cu- and (225)Ac-Labeled FAPI-04 in Pancreatic Cancer Xenograft Mouse Models.
    J Nucl Med. 2020;61:563-569.
    PubMed     Abstract available

  407. VAN WEEHAEGHE D, Van Schoor E, De Vocht J, Koole M, et al
    TSPO Versus P2X7 as a Target for Neuroinflammation: An In Vitro and In Vivo Study.
    J Nucl Med. 2020;61:604-607.
    PubMed     Abstract available

    March 2020
  408. WANG L, Wang M, Yang T, Wu D, et al
    A Prospective, Comparative Study of Planar and Single-photon Emission Computed Tomography Ventilation/Perfusion Imaging for Chronic Thromboembolic Pulmonary Hypertension.
    J Nucl Med. 2020 Mar 20. pii: jnumed.120.243188. doi: 10.2967/jnumed.120.243188.
    PubMed     Abstract available

  409. DE JONG AC, Smits M, van Riet J, Futterer JJ, et al
    (68)Ga-PSMA guided bone biopsies for molecular diagnostics in metastatic prostate cancer patients.
    J Nucl Med. 2020 Mar 13. pii: jnumed.119.241109. doi: 10.2967/jnumed.119.241109.
    PubMed     Abstract available

  410. COLLINGRIDGE D, Barthel H
    A Conversation Between David Collingridge and Henryk Barthel.
    J Nucl Med. 2020;61:307-310.

  411. ZHANG W, Fan W, Ottemann BM, Alshehri S, et al
    Development of Improved Tumor-Residualizing, GRPR-Targeted Agents: Preclinical Comparison of an Endolysosomal Trapping Approach in Agonistic and Antagonistic Constructs.
    J Nucl Med. 2020;61:443-450.
    PubMed     Abstract available

  412. FLOBERG JM, Wang L, Bandara N, Rashmi R, et al
    Alteration of Cellular Reduction Potential Will Change (64)Cu-ATSM Signal With or Without Hypoxia.
    J Nucl Med. 2020;61:427-432.
    PubMed     Abstract available

  413. WU J, Gensheimer MF, Zhang N, Guo M, et al
    Tumor Subregion Evolution-Based Imaging Features to Assess Early Response and Predict Prognosis in Oropharyngeal Cancer.
    J Nucl Med. 2020;61:327-336.
    PubMed     Abstract available

    February 2020
  414. HOPE TA, Bodei L, Chan JA, El-Haddad G, et al
    NANETS/SNMMI Consensus Statement on Patient Selection and Appropriate Use of (177)Lu-DOTATATE Peptide Receptor Radionuclide Therapy.
    J Nucl Med. 2020;61:222-227.

  415. CALAIS J
    FAP: The Next Billion Dollar Nuclear Theranostics Target?
    J Nucl Med. 2020;61:163-165.

  416. ANDERSEN TL, Baun C, Olsen BB, Dam JH, et al
    Improving Contrast and Detectability: Imaging with [(55)Co]Co-DOTATATE in Comparison with [(64)Cu]Cu-DOTATATE and [(68)Ga]Ga-DOTATATE.
    J Nucl Med. 2020;61:228-233.
    PubMed     Abstract available

  417. CECCARINI J, Leurquin-Sterk G, Crunelle CL, de Laat B, et al
    Recovery of Decreased Metabotropic Glutamate Receptor 5 Availability in Abstinent Alcohol-Dependent Patients.
    J Nucl Med. 2020;61:256-262.
    PubMed     Abstract available

  418. HENSBERGEN AW, Buckle T, van Willigen DM, Schottelius M, et al
    Hybrid Tracers Based on Cyanine Backbones Targeting Prostate-Specific Membrane Antigen: Tuning Pharmacokinetic Properties and Exploring Dye-Protein Interaction.
    J Nucl Med. 2020;61:234-241.
    PubMed     Abstract available

  419. MILLER RJH, Manabe O, Tamarappoo B, Hayes S, et al
    Comparative Prognostic and Diagnostic Value of Myocardial Blood Flow and Myocardial Flow Reserve After Cardiac Transplantation.
    J Nucl Med. 2020;61:249-255.
    PubMed     Abstract available

  420. MINARIK D, Enqvist O, Tragardh E
    Denoising of Scintillation Camera Images Using a Deep Convolutional Neural Network: A Monte Carlo Simulation Approach.
    J Nucl Med. 2020;61:298-303.
    PubMed     Abstract available

  421. ZHANG X, Xie Z, Berg E, Judenhofer MS, et al
    Total-Body Dynamic Reconstruction and Parametric Imaging on the uEXPLORER.
    J Nucl Med. 2020;61:285-291.
    PubMed     Abstract available

  422. KLINGENSMITH WC 3RD, Osborne JR
    George de Hevesy in America.
    J Nucl Med. 2020;61:304-305.

  423. ILAN E, Velikyan I, Sandstrom M, Sundin A, et al
    Tumor-to-Blood Ratio for Assessment of Somatostatin Receptor Density in Neuroendocrine Tumors Using (68)Ga-DOTATOC and (68)Ga-DOTATATE.
    J Nucl Med. 2020;61:217-221.
    PubMed     Abstract available

    January 2020
  424. POMPER MG, Choyke PL
    Discussions with Leaders: A Conversation Between Martin Pomper and Peter Choyke.
    J Nucl Med. 2020;61:3-5.

  425. WEBER WA, Bengel FM, Blasberg RG
    The AQARA Principle: Proposing Standard Requirements for Radionuclide-Based Images in Medical Journals.
    J Nucl Med. 2020;61:1-2.

  426. YOO SH, Kang SY, Cheon GJ, Oh DY, et al
    Predictive Role of Temporal Changes in Intratumoral Metabolic Heterogeneity During Palliative Chemotherapy in Patients with Advanced Pancreatic Cancer: A Prospective Cohort Study.
    J Nucl Med. 2020;61:33-39.
    PubMed     Abstract available

  427. MAURER T, Graefen M, van der Poel H, Hamdy F, et al
    Prostate-Specific Membrane Antigen-Guided Surgery.
    J Nucl Med. 2020;61:6-12.
    PubMed     Abstract available

  428. VAN LEEUWEN FWB, Schottelius M, Brouwer OR, Vidal-Sicart S, et al
    Trending: Radioactive and Fluorescent Bimodal/Hybrid Tracers as Multiplexing Solutions for Surgical Guidance.
    J Nucl Med. 2020;61:13-19.
    PubMed     Abstract available

  429. PANTEL AR, Viswanath V, Daube-Witherspoon ME, Dubroff JG, et al
    PennPET Explorer: Human Imaging on a Whole-Body Imager.
    J Nucl Med. 2020;61:144-151.
    PubMed     Abstract available

  430. CARLOS DOS SANTOS J, Beijer B, Bauder-Wust U, Schafer M, et al
    Development of Novel PSMA Ligands for Imaging and Therapy with Copper Isotopes.
    J Nucl Med. 2020;61:70-79.
    PubMed     Abstract available

  431. KARP JS, Viswanath V, Geagan MJ, Muehllehner G, et al
    PennPET Explorer: Design and Preliminary Performance of a Whole-Body Imager.
    J Nucl Med. 2020;61:136-143.
    PubMed     Abstract available

    December 2019
  432. HERNANDEZ R, Grudzinski JJ, Aluicio-Sarduy E, Massey CF, et al
    (177)Lu-NM600 targeted radionuclide therapy extends survival in syngeneic murine models of triple-negative breast cancer.
    J Nucl Med. 2019 Dec 20. pii: jnumed.119.236265. doi: 10.2967/jnumed.119.236265.
    PubMed     Abstract available

  433. ARNON-SHELEG E, Haberfeld O, Kremer R, Keidar Z, et al
    Head to head prospective comparison of quantitative lung scintigraphy and segment counting in predicting pulmonary function of lung cancer patients undergoing video-assisted thoracoscopic lobectomy.
    J Nucl Med. 2019 Dec 20. pii: jnumed.119.234526. doi: 10.2967/jnumed.119.234526.
    PubMed     Abstract available

  434. MCDONALD ES, Doot RK, Young AJ, Schubert EK, et al
    Breast Cancer (18)F-ISO-1 Uptake as a Marker of Proliferation Status.
    J Nucl Med. 2019 Dec 13. pii: jnumed.119.232363. doi: 10.2967/jnumed.119.232363.
    PubMed     Abstract available

    November 2019
  435. MEERSHOEK P, Buckle T, van Oosterom MN, KleinJan GH, et al
    Can fluorescence-guided surgery help identify all lesions in unknown locations or is the integrated use of a roadmap created by preoperative imaging mandatory? A blinded study in prostate cancer patients.
    J Nucl Med. 2019 Nov 11. pii: jnumed.119.235234. doi: 10.2967/jnumed.119.235234.
    PubMed     Abstract available

  436. HABERKORN U, Czernin J
    A Conversation Between Uwe Haberkorn and Johannes Czernin.
    J Nucl Med. 2019;60:1495-1498.

  437. SAADANI H, van der Hiel B, Aalbersberg EA, Zavrakidis I, et al
    Metabolic Biomarker-Based BRAFV600 Mutation Association and Prediction in Melanoma.
    J Nucl Med. 2019;60:1545-1552.
    PubMed     Abstract available

  438. GARCIA EV, Slomka P, Moody JB, Germano G, et al
    Quantitative Clinical Nuclear Cardiology, Part 1: Established Applications.
    J Nucl Med. 2019;60:1507-1516.
    PubMed     Abstract available

  439. PEREIRA PMR, Mandleywala K, Ragupathi A, Carter LM, et al
    Temporal Modulation of HER2 Membrane Availability Increases Pertuzumab Uptake and Pretargeted Molecular Imaging of Gastric Tumors.
    J Nucl Med. 2019;60:1569-1578.
    PubMed     Abstract available

  440. KHERA E, Zhang L, Roberts S, Nessler I, et al
    Blocking of Glucagonlike Peptide-1 Receptors in the Exocrine Pancreas Improves Specificity for beta-Cells in a Mouse Model of Type 1 Diabetes.
    J Nucl Med. 2019;60:1635-1641.
    PubMed     Abstract available

    September 2019
  441. ROTTENBURGER C, Nicolas GP, McDougall L, Kaul F, et al
    Cholecystokinin-2 Receptor Agonist (177)Lu-PP-F11N for Radionuclide Therapy of Medullary Thyroid Carcinoma - Results of the Lumed Phase 0a Study.
    J Nucl Med. 2019 Sep 13. pii: jnumed.119.233031. doi: 10.2967/jnumed.119.233031.
    PubMed     Abstract available

  442. GHAFOOR S, Burger IA, Vargas HA
    Multimodality Imaging of Prostate Cancer.
    J Nucl Med. 2019 Sep 3. pii: jnumed.119.228320. doi: 10.2967/jnumed.119.228320.
    PubMed     Abstract available

    August 2019
  443. VARASTEH Z, Mohanta S, Robu S, Braeuer M, et al
    Molecular imaging of fibroblast activity after myocardial infarction using a (68)Ga-labelled fibroblast activation protein inhibitor FAPI-04.
    J Nucl Med. 2019 Aug 12. pii: jnumed.119.226993. doi: 10.2967/jnumed.119.226993.
    PubMed     Abstract available

    July 2019

  444. Lawhn-Heath Named 2019 Henkin Fellow.
    J Nucl Med. 2019;60:14N.

    SNMMI Leadership Update: Influx of New Ideas and Opportunities Collaboration Propels Growth.
    J Nucl Med. 2019;60:13N.

  446. SEGALL GM
    The Distinction Between an AU and an ABNM-Certified MD.
    J Nucl Med. 2019;60:10N.

  447. HOPE TA, Abbott A, Colucci K, Bushnell DL, et al
    NANETS/SNMMI Procedure Standard for Somatostatin Receptor-Based Peptide Receptor Radionuclide Therapy with (177)Lu-DOTATATE.
    J Nucl Med. 2019;60:937-943.
    PubMed     Abstract available

  448. REILLY RM
    Immuno-PET to Optimize the Dose of Monoclonal Antibodies for Cancer Therapy: How Much Is Enough?
    J Nucl Med. 2019;60:899-901.

  449. LUTJE S, Franssen GM, Herrmann K, Boerman OC, et al
    In Vitro and In Vivo Characterization of an (18)F-AlF-Labeled PSMA Ligand for Imaging of PSMA-Expressing Xenografts.
    J Nucl Med. 2019;60:1017-1022.
    PubMed     Abstract available

    June 2019

  450. NRC Advisory Committee on Medical Uses of Isotopes Spring Meeting.
    J Nucl Med. 2019;60:19N.

  451. Outstanding JNMT Articles for 2018.
    J Nucl Med. 2019;60:17N.

  452. Best JNM Articles for 2018.
    J Nucl Med. 2019;60:16N.

  453. GREENSPAN BS, Ahuja S, Avram AM, Gulec S, et al
    Overview of the Martinique Meetings: What Has Been Established and Where Are We Going?
    J Nucl Med. 2019;60:15N.

  454. VOLKOW N, Czernin J
    A Conversation Between Nora Volkow and Johannes Czernin.
    J Nucl Med. 2019;60:717-720.

  455. MEERSHOEK P, van den Berg NS, Brouwer OR, Teertstra HJ, et al
    Three-Dimensional Tumor Margin Demarcation Using the Hybrid Tracer Indocyanine Green-(99m)Tc-Nanocolloid: A Proof-of-Concept Study in Tongue Cancer Patients Scheduled for Sentinel Node Biopsy.
    J Nucl Med. 2019;60:764-769.
    PubMed     Abstract available

  456. EMMETT L, Metser U, Bauman G, Hicks RJ, et al
    Prospective, Multisite, International Comparison of (18)F-Fluoromethylcholine PET/CT, Multiparametric MRI, and (68)Ga-HBED-CC PSMA-11 PET/CT in Men with High-Risk Features and Biochemical Failure After Radical Prostatectomy: Clinical Performance and P
    J Nucl Med. 2019;60:794-800.
    PubMed     Abstract available

    May 2019
  457. SATHEKGE M, Bruchertseifer F, Vorster M, Lawal I, et al
    J Nucl Med. 2019 May 17. pii: jnumed.119.229229. doi: 10.2967/jnumed.119.229229.
    PubMed     Abstract available

  458. CARRASQUILLO JA, Fine B, Pandit-Taskar N, Larson SM, et al
    Imaging metastatic castration-resistant prostate cancer patients with (89)Zr-DFO-MSTP2109A anti-STEAP1 antibody.
    J Nucl Med. 2019 May 3. pii: jnumed.118.222844. doi: 10.2967/jnumed.118.222844.
    PubMed     Abstract available

  459. FDA Updates Bulk Drug Substances List.
    J Nucl Med. 2019;60:8N.

  460. SCHWAIGER M, Czernin J
    A Conversation Between Markus Schwaiger and Johannes Czernin.
    J Nucl Med. 2019;60:573-576.

  461. KELLY JM, Amor-Coarasa A, Ponnala S, Nikolopoulou A, et al
    Albumin-Binding PSMA Ligands: Implications for Expanding the Therapeutic Window.
    J Nucl Med. 2019;60:656-663.
    PubMed     Abstract available

    April 2019
  462. JANSEN BHE, Yaqub M, Voortman J, Cysouw MCF, et al
    Simplified Methods for Quantification of (18)F-DCFPyL Uptake in Patients with Prostate Cancer.
    J Nucl Med. 2019 Apr 18. pii: jnumed.119.227520. doi: 10.2967/jnumed.119.227520.
    PubMed     Abstract available

  463. ABIODUN-OJO OA, Akintayo AA, Akin-Akintayo OO, Tade FI, et al
    (18)F-Fluciclovine parameters on targeted prostate biopsy associated with true positivity in recurrent prostate cancer.
    J Nucl Med. 2019 Apr 6. pii: jnumed.119.227033. doi: 10.2967/jnumed.119.227033.
    PubMed     Abstract available

    March 2019
  464. GEISLER S, Stegmayr C, Niemietz N, Lohmann P, et al
    Treatment-related uptake of O-(2-[(18)F]fluoroethyl)-L-tyrosine and L-[methyl-(3)H]-methionine after tumor resection in rat glioma models.
    J Nucl Med. 2019 Mar 8. pii: jnumed.119.225680. doi: 10.2967/jnumed.119.225680.
    PubMed     Abstract available

  465. KRAMER GM, Yaqub M, Vargas HA, Schuit R, et al
    Assessment of simplified methods for quantification of (18)F-FDHT uptake in patients with metastatic castration-resistant prostate cancer.
    J Nucl Med. 2019 Mar 8. pii: jnumed.118.220111. doi: 10.2967/jnumed.118.220111.
    PubMed     Abstract available

    February 2019
  466. LIU T, Liu C, Xu X, Liu F, et al
    Preclinical evaluation and pilot clinical study of Al(18)F-PSMA-BCH for prostate cancer imaging.
    J Nucl Med. 2019 Feb 22. pii: jnumed.118.221671. doi: 10.2967/jnumed.118.221671.
    PubMed     Abstract available

    November 2018
  467. BEHR SC, Aggarwal R, Van Brocklin HF, Flavell RR, et al
    First-in-Human Phase I study of CTT1057, a Novel (18)F Labeled Imaging Agent with Phosphoramidate Core Targeting Prostate Specific Membrane Antigen in Prostate Cancer.
    J Nucl Med. 2018 Nov 21. pii: jnumed.118.220715. doi: 10.2967/jnumed.118.220715.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Nuclear Medicine is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.